[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_19791e10-50d2-4852-8112-4a2ac91ba198":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:19791e10-50d2-4852-8112-4a2ac91ba198,\"}":61},{"code":4,"data":5,"meta":20},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":22,"manageAffiliations":23,"indexDatabases":24,"url":20,"thumbnailPath":20,"statistic":42,"gsStatistic":20,"type":20,"analyzePriority":20},"19791e10-50d2-4852-8112-4a2ac91ba198","2024-04-14T04:34:38.197+00:00","2025-11-21T09:58:06.805+00:00",[],"Springer-Science-and-Business-Media-LLC",{"issn":12,"eissn":14,"title":16},{"VOID":13},"1544-1865",{"VOID":15},"1544-225X",{"EN":17},"Springer Science and Business Media LLC","PUBLISHER","PENDING",null,0,[],[],[25],{"id":26,"indexDatabase":27,"url":39,"indexYears":40,"academicFieldIds":20,"indexDatabaseRanking":41},"8b82ea68-a9a1-4023-9af6-eb7bf41046e7",{"id":28,"createTime":29,"updateTime":30,"relativeEntities":31,"label":32,"description":34,"key":36,"publicationTags":37,"standard":20},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":33,"VI":33},"Scopus - Elsevier",{"EN":33,"VI":35},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[38],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F5000156914","2006-2009","SCOPUS__Q4",{"impactFactor":21,"impactFactorByYear":43,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":44,"totalPublicationByYear":45,"totalCitation":52,"totalCitationByYear":53,"totalCitationPerPublication":57,"totalCitationPerPublicationByYear":58,"hindexLast5Year":55,"hindex":55},{},111,{"2003":46,"2004":47,"2005":48,"2006":48,"2007":49,"2008":50,"2009":51},7,21,16,19,20,12,6,{"2004":54,"2006":55,"2008":56},3,2,1,0.05,{"2004":59,"2006":60,"2008":57},0.14,0.12,{"meta":62,"data":64},{"total":63},"111",[65,144,211,285,537,597,660,706,764,831],{"id":66,"createTime":67,"updateTime":68,"relativeEntities":69,"slug":70,"properties":71,"entityType":80,"verifyStatus":19,"verifyTime":68,"verifyNote":81,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":82,"fullTextUrl":20,"authors":83,"publicationType":114,"publisherRelationship":115,"citationCount":20,"citationInfo":20,"publishDate":141,"publishYear":142,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":143},"67eacfb4-0637-4342-ad5d-ce8b0d6f4f4e","2024-01-08T11:01:08.658+00:00","2025-02-13T23:49:21.828+00:00",[],"Review-of-adolescent-urinary-tract-infection",{"references":72,"abstract":74,"title":76,"doi":78},{"VOID":73},"Ziv A, Boulet J, Slap G: Emergency department utilization by adolescents in the United States. Pediatrics 1998, 101:987–994.\nZiv A, Boulet J, Slap G: Utilization of physicians offices by adolescents in the United States. Pediatrics 1999, 104:35.\nFoxman B, Barlow R, D’Arcy H: Urinary tract infections: self-reported incidence and associated costs. Ann Epidemiol 2000, 10:509–515.\nHooton TM, Scholes D, Stapleton AE, et al.: A prospective study of asymptomatic bacteriuria in sexually active young women. N Eng J Med 2000, 343:992–997.\nNicolle LE: Asymptomatic bacteriuria: review and discussion of the IDSA guidelines. Int J Antimicrob Agents 2006, 28(Suppl):42–48.\nRaz R, Colodner R, Kunin CM: Who are you-Staphylococcus saprophyticus? Clin Infect Dis 2005, 40:896–898.\nHedman P, Ringertz O: Urinary tract infections caused by Staphylococcus Saprophyticus. A matched case control study. J Infect 1991, 23:145–153.\nFihn SD, Boyko EJ, Chen CL: Use of spermicide-coated condoms and other risk factors for urinary tract infections caused by Staphylococcus Saprophyticus. Arch Intern Med 1998, 158:281.\nGuidoni EB, Toporovski J: Urinary tract infections in adolescents. J Pediatr 2001, 77:165.\nScholes D, Hooton T, Roberts P: Risk factors for recurrent urinary tract infections in young women. J Infect Dis 2000, 182:1177.\nNguyen H, Weir M: Urinary tract infection as a possible marker for teenage sex. South Med J 2002, 95:867–869.\nStamatiou C, Bovis C, Panagopolous P: Sex-induced cystitis—patient burden and other epidemiological features. Clin Exp Obstet Gynecol 2005, 32:180–182.\nStamatiou C, Petrakos G, Bovis C: Efficacy of prophylaxis in women with sex-induced cystitis. Clin Exp Obstet Gynecol 2005, 32:193–195.\nBerg E, Benson D, Haraskiewicz P: High prevalence of sexually transmitted diseases in women with urinary infections. Acad Emerg Med 1996, 3:1030–1034.\nHuppert JS, Biro FM, Mehrabi J, Slap GB: Urinary tract infection and chlamydia infection in adolescent females. J Pediatr Adolesc Gynecol 2003, 16:133–137.\nAbarbanel J, Engelstein D, Lask D, Livine PM: Urinary tract infection in men younger than 45 years of age: is there a need for urologic investigation? Urology 2003, 62:27–29.\nKrieger JN, Ross SD, Simonsen JM: Urinary tract infections in healthy university men. J Urol 1993, 149:1046–1048.\nKhan A, Schaeffer H, Evans H: Urinary tract infections in adolescent boys. J Natl Med Assoc 1996, 88:217.\nChroustova D, Palyzova D, Urbanova I, Kolska M: Results of a five-year study of 99mTc DMSA renal scintigraphy in children and adolescents following acute pyelonephritis. Nucl Med Rev Cent East Eur 2006, 9:46–50.\nvan Haarst EP, van Andel G, Heldeweg EA, et al.: Evaluation of the diagnostic work-up in young women referred for recurrent lower urinary tract infections. Urology 2001, 57:1068–1072.\nGargollo PC, Kozakewich HP, Bauer SB, et al.: Balanitis xerotica obliterans in boys. J Urol 2005, 174:1409–1412.\nYeung CK, Sihoe JD, Sit FK: Characteristics of primary nocturnal enuresis in adults: an epidemiological study. BJU Int 2004, 93:341–345.\nNappo S, Del Gade R, Chiozz ML, et al.: Nocturnal enuresis in the adolescent: a neglected problem. BJU Int 2002, 90:912–917.\nBakker E, van Gool J, van Sprundel M, et al.: Risk factors for recurrent urinary tract infection in 4332 Belgian schoolchildren aged between 10 and 14 years. Eur J Pediatr 2004, 163:234–238.\nBower WF, Sit FKY, Yeung CK: Nocturnal enuresis in adolescents and adults is associated with childhood elimination syndromes. J Urol 2006, 176:1771–1775.\nHerz D, Weiser A, Collette T, et al.: Dysfunctional elimination syndrome as an etiology of idiopathic urethritis in childhood. J Urol 2005, 173:2132–2137.\nLi Y, Oi L, Wen JG, et al.: Chronic prostatitis during puberty. BJU Int 2006, 98:818–821.\nGrether JK, Nelson KB: Maternal infection and cerebral palsy in infants of normal birthweight. JAMA 1997, 278:207–211.\nMcDermott S, Callaghan W, Szwejbka L, et al.: Urinary tract infections during pregnancy and mental retardation and development delay. Obstet Gynecol 2000, 96:113–119.\nDuff P: Antibiotic selection in obstetrics; making cost effective choices. Clin Obstet Gynecology 2002, 45:59–72.\nBeetz R, Mannhardt W, Fisch M, et al.: Long-term followup of 158 young adults surgically treated for vesicoureteral reflux in childhood:the ongoing risk of urinary tract infections. J Urol 2002, 168:704–707.\nGaspari RJ, Dickson E, Karlowsky J, Doern G: Multidrug resistance in pediatric urinary tract infections. Microb Drug Resist 2006, 12:126–129.\nCommittee on infectious diseases: The use of systemic fluoroquinolones. Pediatrics 2006, 118:1287–1292.\nGupta K, Hooton TM, Roberts PL, Stamm WE: Patient initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med 2001, 135:9–16.",{"EN":75},"The diagnosis and management of adolescent urinary tract infection (UTI) shares some of the clinical features seen in infections of the young and old. Whereas most infections in the young patient demand an extensive radiologic work-up, the teenager with a UTI is not so straightforward. The clinical must balance being too aggressive with being too conservative in the diagnosis and management of these patients. UTIs occur most frequently among adolescent females and are usually uncomplicated and not associated with underlying anatomic abnormalities. Smaller numbers of adolescent males suffer from UTIs, and the need to search for underlying abnormalities is not clear. Adolescent UTI is associated with nascent sexual activity and is also more common in voiding\u002Felimination syndromes. Future studies examining UTI, specifically in the adolescent age group, will help provide clinicians with a more focused algorithm in the diagnosis and management of adolescent UTIs.",{"EN":77},"Review of adolescent urinary tract infection",{"VOID":79},"10.1007\u002Fs11918-007-0005-8","PUBLICATION","Author affiliation is blank","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11918-007-0005-8",[84,92],{"id":85,"sortIndex":56,"researcher":20,"roles":86,"affiliations":88,"properties":89},"252aa17e-ce87-48f1-9fe5-3f101dbc5aed",[87],"AUTHOR",[],{"title":90},{"VI":91},"Jacob Cohen",{"id":93,"sortIndex":21,"researcher":20,"roles":94,"affiliations":95,"properties":111},"da785ea7-9fd3-43e1-ba3f-ed931f50f7c1",[87],[96],{"id":97,"sortIndex":21,"affiliation":98,"properties":108},"0fbf0024-db3f-4427-8c90-5546afb721d4",{"id":99,"createTime":100,"updateTime":101,"relativeEntities":102,"slug":103,"properties":104,"entityType":107,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"ccc614c8-89f7-486a-b002-000a5155fbf9","2024-09-17T11:05:24.655+00:00","2024-10-10T09:03:50.671+00:00",[],"SUNY-Downstate-Medical-Center-Brooklyn-United-States",{"title":105},{"EN":106},"SUNY Downstate Medical Center, Brooklyn, United States","AFFILIATION",{"title":109},{"VI":110},"SUNY Downstate Medical Center, Brooklyn, USA",{"title":112},{"VI":113},"Mark Horowitz","ARTICLE",{"url":82,"publisher":116,"properties":136},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":117,"slug":10,"properties":118,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":122,"manageAffiliations":123,"indexDatabases":124,"url":20,"thumbnailPath":20,"statistic":131,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":119,"eissn":120,"title":121},{"VOID":13},{"VOID":15},{"EN":17},[],[],[125],{"id":26,"indexDatabase":126,"url":39,"indexYears":40,"academicFieldIds":20,"indexDatabaseRanking":41},{"id":28,"createTime":29,"updateTime":30,"relativeEntities":127,"label":128,"description":129,"key":36,"publicationTags":130,"standard":20},[],{"EN":33,"VI":33},{"EN":33,"VI":35},[38],{"impactFactor":21,"impactFactorByYear":132,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":44,"totalPublicationByYear":133,"totalCitation":52,"totalCitationByYear":134,"totalCitationPerPublication":57,"totalCitationPerPublicationByYear":135,"hindexLast5Year":55,"hindex":55},{},{"2003":46,"2004":47,"2005":48,"2006":48,"2007":49,"2008":50,"2009":51},{"2004":54,"2006":55,"2008":56},{"2004":59,"2006":60,"2008":57},{"volume":137,"pages":139},{"VOID":138},"5",{"VOID":140},"35-39","2007-04-16",2007,false,{"id":145,"createTime":146,"updateTime":147,"relativeEntities":148,"slug":149,"properties":150,"entityType":80,"verifyStatus":19,"verifyTime":147,"verifyNote":81,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":159,"fullTextUrl":20,"authors":160,"publicationType":114,"publisherRelationship":183,"citationCount":20,"citationInfo":20,"publishDate":209,"publishYear":210,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":143},"dd53310c-c53a-4799-895b-07573816cced","2023-11-29T22:36:21.358+00:00","2024-12-15T23:40:15.359+00:00",[],"The-role-of-botulinum-toxin-a-in-the-management-of-lower-urinary-tract-symptoms",{"references":151,"abstract":153,"title":155,"doi":157},{"VOID":152},"Kirby RS: The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 2000, 56:3–6.\nPlatz EA, Smit E, Curhan GC, et al.: Prevalence of and racial\u002Fethnic variation in lower urinary tract symptoms and noncancer prostate surgery in US men. Urology 2002, 59:877–883.\nHald T: Urodynamics in benign prostatic hyperplasia: a survey. Prostate Suppl 1989, 2:69–77.\nBarry MJ, Fowler FJ Jr, Bin L, Oesterling JE: A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer. J Urol 1997, 158:488–491, discussion 492.\nKortt MA, Bootman JL: The economics of benign prostatic hyperplasia treatment: a literature review. Clin Ther 1996, 18:1227–1241.\nVerhamme KM, Dieleman JP, Bleumink GS, et al.: Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 2003, 44:539–545.\nBall AJ, Feneley RC, Abrams PH: The natural history of untreated “prostatism.” Br J Urol 1981, 53:613–616.\nNickel JC: Benign prostatic hyperplasia: does prostate size matter? Rev Urol 2003, 5:S12–S17.\nLin VK, Wang D, Lee IL, et al.: Myosin heavy chain gene expression in normal and hyperplastic human prostate tissue. Prostate 2000, 44:193–203.\nRiehmann M, Bruskewitz R: Transurethral incision of the prostate and bladder neck. J Androl 1991, 12:415–422.\nShapiro E, Tsitlik JE, Lepor H: Alpha 2 adrenergic receptors in canine prostate: biochemical and functional correlations. J Urol 1987, 137:565–570.\nKaplan SA, Goluboff ET, Olsson CA, et al.: Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology 1995, 45:398–405.\nSavoca G, De Stefani S, Gattuccio I, et al.: Percutaneous ethanol injection of the prostate as minimally invasive treatment for benign prostatic hyperplasia: preliminary report. Eur Urol 2001, 40:504–508.\nPlante MK, Gross AL, Kliment J, et al.: Intraprostatic ethanol chemoablation via transurethral and transperineal injection. BJU Int 2003, 91:94–98.\nPlante MK, Bunnell ML, Trotter SJ, et al.: Transurethral prostatic tissue ablation via a single needle delivery system: initial experience with radio-frequency energy and ethanol. Prostate Cancer Prostatic Dis 2002, 5:183–188.\nDuchen LW: Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles. J Neurol Neurosurg Psychiatry 1970, 33:40–54.\nChuang YC, Chancellor MB: The application of botulinum toxin in the prostate. J Urol 2006, 176:2375–2382.\nKanagawa K, Sugimura K, Kuratsukuri K, et al.: Norepinephrine activates P44 and P42 MAPK in human prostate stromal and smooth muscle cells but not in epithelial cells. Prostate 2003, 56:313–318.\nHedlund H, Andersson KE: Comparison of the responses to drugs acting on adrenoreceptors and muscarinic receptors in human isolated corpus cavernosum and cavernous artery. J Auton Pharmacol 1985, 5:81–88.\nThiyagarajan M, Kaul CL, Ramarao P: Enhancement of alpha-adrenoceptor-mediated responses in prostate of testosterone-treated rat. Eur J Pharmacol 2002, 453:335–344.\nRoehrborn CG: Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors. Rev Urol 2004, 6:121–127.\nHansson J, Bjartell A, Gadaleanu V, et al.: Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate 2002, 53:50–59.\nLin AT, Yang AH, Chen KK: Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol 2007, 52:582–589.\nMorris JL, Jobling P, Gibbins IL: Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons. Am J Physiol Heart Circ Physiol 2002, 283:H2627–H2635.\nJung HH, Lauterburg T, Burgunder JM: Expression of neurotransmitter genes in rat spinal motoneurons after chemodenervation with botulinum toxin. Neuroscience 1997, 78:469–479.\nScott AB: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 1980, 17:21–25.\nDykstra DD, Sidi AA, Scott AB, et al.: Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988, 139:919–922.\nMaria G, Brisinda G, Civello IM, et al.: Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003, 62:259–264, discussion 264–265.\nKuo HC: Prostate botulinum A toxin injection—an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005, 65:670–674.\nLarson TR, Huidobro C, Acevedo C, et al.: Intraprostatic injection of botulinum toxin in the treatment of symptomatic LUTS, including sequential MRIS for accurate changes in size of the prostate [abstract 1386]. Presented at the American Urological Association Annual Meeting. San Antonio, TX; May 21–26, 2005.\nSilva J, Silva C, Saraiva L, et al.: Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol 2008, 53:153–159.\nPark DS, Cho TW, Lee YK, et al.: Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med J 2006, 47:706–714.\nChuang YC, Chiang PH, Yoshimura N, et al.: Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 2006, 98:1033–1037, discussion 1337.",{"EN":154},"Lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH) is the most common disease affecting men older than age 40. Although rarely life threatening, BPH may significantly affect quality of life. The mainstay nonsurgical therapy for BPH includes α-adrenergic blockade and\u002For 5-α-reductase inhibitors. However, current regimens require the daily administration of medication for an indefinite time. Botulinum toxin type A (BTX-A) is an injectable neurotoxin indicated to treat blepharospasm, strabismus, axillary hyperhydrosis, cervical dystonia, and glabellar lines. When injected intraprostatically, BTX-A may treat BPH-related symptoms. This article reviews evidence of BTX-A safety and efficacy in the treatment of LUTS related to BPH. Results are also presented from our first phase 1, dose-escalating study to evaluate the dose-related toxicity of BTX-A to treat LUTS due to BPH. Ultimately, the LUTS-related improvements seen in our study were consistent with earlier published trials using BTX-A to treat LUTS.",{"EN":156},"The role of botulinum toxin a in the management of lower urinary tract symptoms",{"VOID":158},"10.1007\u002Fs11918-008-0018-y","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11918-008-0018-y",[161,168],{"id":162,"sortIndex":56,"researcher":20,"roles":163,"affiliations":164,"properties":165},"b610f072-3267-4330-8670-b760157732f6",[87],[],{"title":166},{"VI":167},"E. David Crawford",{"id":169,"sortIndex":21,"researcher":20,"roles":170,"affiliations":171,"properties":180},"feb916b8-ff37-4817-90d9-92a6e498de50",[87],[172],{"id":20,"sortIndex":21,"affiliation":173,"properties":20},{"id":174,"createTime":175,"updateTime":175,"relativeEntities":176,"slug":20,"properties":177,"entityType":107,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"91f0aba9-9b27-43c5-9055-c0d2b0e4f76e","2023-11-29T22:36:21.362+00:00",[],{"title":178},{"VI":179},"Section of Urologic Oncology, University of Colorado Health Science Center, Anschutz Cancer Pavilion, Aurora, USA",{"title":181},{"VI":182},"Al B. Barqawi",{"url":159,"publisher":184,"properties":204},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":185,"slug":10,"properties":186,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":190,"manageAffiliations":191,"indexDatabases":192,"url":20,"thumbnailPath":20,"statistic":199,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":187,"eissn":188,"title":189},{"VOID":13},{"VOID":15},{"EN":17},[],[],[193],{"id":26,"indexDatabase":194,"url":39,"indexYears":40,"academicFieldIds":20,"indexDatabaseRanking":41},{"id":28,"createTime":29,"updateTime":30,"relativeEntities":195,"label":196,"description":197,"key":36,"publicationTags":198,"standard":20},[],{"EN":33,"VI":33},{"EN":33,"VI":35},[38],{"impactFactor":21,"impactFactorByYear":200,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":44,"totalPublicationByYear":201,"totalCitation":52,"totalCitationByYear":202,"totalCitationPerPublication":57,"totalCitationPerPublicationByYear":203,"hindexLast5Year":55,"hindex":55},{},{"2003":46,"2004":47,"2005":48,"2006":48,"2007":49,"2008":50,"2009":51},{"2004":54,"2006":55,"2008":56},{"2004":59,"2006":60,"2008":57},{"volume":205,"pages":207},{"VOID":206},"6",{"VOID":208},"117-122","2008-10-16",2008,{"id":212,"createTime":213,"updateTime":214,"relativeEntities":215,"slug":216,"properties":217,"entityType":80,"verifyStatus":226,"verifyTime":214,"verifyNote":227,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":228,"fullTextUrl":20,"authors":229,"publicationType":114,"publisherRelationship":257,"citationCount":20,"citationInfo":20,"publishDate":283,"publishYear":284,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":143},"d88fe4f8-5055-44b9-973f-a9a97c9ed440","2024-01-02T03:43:09.211+00:00","2025-01-07T23:16:22.758+00:00",[],"Radical-prostatectomy-for-the-patient-with-locally-advanced-prostate-cancer",{"references":218,"abstract":220,"title":222,"doi":224},{"VOID":219},"Stanford J, Stephenson R, Coyle L, et al.: Prostate Cancer Trends, 1973–1995. Bethesda: NIH Pub No 99-4543; 1999.\nStephenson RA: Prostate cancer trends in the era of prostatespecific antigen: an update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002, 29:173–181.\nCheng L, Zincke H, Blute ML, et al.: Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001, 91:66–73. Combination radical prostatectomy and immediate hormonal therapy in patients with micrometastatic lymph node involvement provides progression-free and cancer-specific survival rates statistically similar to patients without lymph node involvement in a multivariate setting, which controls for other pathologic variables. Micrometastatic disease within the lymph nodes on frozen section examination during planned radical prostatectomy should not be the reason for abandoning prostate extirpation.\nZincke H, Fleming TR, Furlow WL, et al.: Radical retropubic prostatectomy and pelvic lymphadenectomy for high-stage cancer of the prostate. Cancer 1981, 47:1901–1910.\nZincke H, Utz DC, Taylor WF: Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol 1986, 135:1199–1205.\nMorgan WR, Bergstralh EJ, Zincke H: Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer [comment]. Urology 1993, 41:113–120.\nLerner SE, Blute ML, Zincke H: Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 1995, 154:1447–1452.\nAmling CL, Leibovich BC, Lerner SE, et al.: Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Semin Urol Oncol 1997, 15:215–221.\nBarry MJ, Albertsen PC, Bagshaw MA, et al.: Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001, 91:2302–2314. A retrospective study of the outcomes in men with prostate cancer treated with watchful waiting, radiation therapy, or radical prostatectomy. Using case-control matching and multivariate analysis, this study is the closest we have come to a randomized trial of treatment outcome for men with prostate cancer.\nAmling CL, Blute ML, Lerner SE, et al.: Influence of prostatespecific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice [comment]. Mayo Clin Proc 1998, 73:401–406.\nThompson IM: Clinical stage C carcinoma of the prostate. AUA Update 1993, 12:82–87.\nMeltzer D, Egleston B, Abdalla I: Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health 2001, 91:126–128. Distinct patterns of treatment for newly diagnosed prostate cancer are present within medical practice. Some of these patterns may be based on antiquated ideas regarding the proper management of advanced prostate disease.\nCatalona WJ: Radical surgery for advanced prostate cancer and for radiation failures [comment]. J Urol 1992, 147:916.\nSteinberg GD, Walsh PC: Expanding role in the management of patients with adenocarcinoma of the prostate. Prob Urol 1990, 4:408–419.\nMoul JW: The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer 1991, 68:1265–1271.\nBoxer RJ, Kaufman JJ, Goodwin WE: Radical prostatectomy for carcinoma of the prostate 1951–1976: a review of 329 patients. J Urol 1977, 117:208–213.\nElder JS, Jewett HJ, Walsh PC: Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate. J Urol 1982, 127:704–706.\nFuks Z, Leibel SA, Wallner KE, et al.: The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 1991, 21:537–547.\nZagars GK, von Eschenbach AC, Ayala AG, et al.: The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer 1991, 68:2370–2377.\nKuban DA, el-Mahdi AM, Schellhammer PF: Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. Urology 1987, 30:420–426.\nTomlinson RL, Currie DP, Boyce WH: Radical prostatectomy: palliation for stage C carcinoma of the prostate. J Urol 1977, 117:85–87.\nPaulson DF, Hodge GB Jr, Hinshaw W: Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate. J Urol 1984, 131:901–902.\nde Vere White R, Paulson DF, Glenn JF: The clinical spectrum of prostate cancer. J Urol 1977, 117:323–327.\nPavone-Macaluso M, de Voogt HJ, Viggiano G, et al.: Comparison of diethylstilbestrol, cyproterone acetate, and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986, 136:624–631.\nBagshaw MA, Cox RS, Ray GR: Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr 1988, 7:47–60.\nLeibel SA, Fuks Z, Zelefsky MJ, Whitmore WF Jr: The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement [comment]. Int J Radiat Oncol Biol Phys 1994, 28:7–16.\nKaplan ID, Prestidge BR, Bagshaw MA, Cox RS: The importance of local control in the treatment of prostatic cancer. J Urol 1992, 147:917–921.\nCoen JJ, Zietman AL, Thakral H, Shipley WU: Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases [see comments]. J Clin Oncol 2002, 20:3199–3205. Examined 1469 patients who were receiving external beam radiotherapy with a curative intent for adenocarcinoma of the prostate. Failure to control the cancer locally was the strongest predictor of distant metastasis. More than two thirds of the patients with clinical locally advanced prostate cancer at treatment fail locally and progress more rapidly distally. There is danger in failing to control the locally advanced prostate cancer with radiotherapy.\nZietman AL, Westgeest JC, Shipley WU: Radiation-based approaches to the management of T3 prostate cancer. Semin Urol Oncol 1997, 15:230–238.\nCrook JM, Perry GA, Robertson S, Esche BA: Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients [comment]. Urology 1995, 45:624–631.\nDugan TC, Shipley WU, Young RH, et al.: Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels [comment]. J Urol 1991, 146:1313–1316.\nLaverdiere J, Gomez JL, Cusan L, et al.: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer [comment]. Int J Radiat Oncol Biol Phys 1997, 37:247–252.\nBolla M, Gonzalez D, Warde P, et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295–300.\nZincke H, Bergstralh EJ, Blute ML, et al.: Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution [comment]. J Clin Oncol 1994, 12:2254–2263.\nPadula GD, Zelefsky MJ, Venkatraman ES, et al.: Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer [comment]. International J Radiat Oncol Biol Phys 2002, 52:439–443.\nPilepich MV, Winter K, John MJ, et al.: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. International J Radiat Oncol Biol Phys 2001, 50:1243–1252. Combination radiotherapy and hormonal therapy does not effectively control high-grade\u002Fhigh-volume prostate cancer locally or at distant sites. Few patients with cT3 prostate cancer have low-grade\u002F low-volume prostate cancer, which appears to respond to this form of multimodality therapy.\nKuban DA, el-Mahdi AM, Schellhammer PF: Prognosis in patients with local recurrence after definitive irradiation for prostatic carcinoma. Cancer 1989, 63:2421–2425.\nKoprowski CD, Berkenstock KG, Borofski AM, et al.: External beam irradiation versus 125 iodine implant in the definitive treatment of prostate carcinoma [comment]. Int J Radiat Oncol Biol Phys 1991, 21:955–960.\nScardino PT: Is radiotherapy effective for locally advanced (stage C or T3) prostate cancer? Prog Clin Biol Res 1989, 303:223–239.\nWhitmore WF Jr, Hilaris B, Sogani P, et al.: Interstitial irradiation using I-125 seeds. Prog Clin Biol Res 1987, 243B:177–195.\nHolzman M, Carlton CE Jr, Scardino PT: The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer. J Urol 1991, 146:1578–1582.\nPartin AW, Kattan MW, Subong EN, et al.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update [erratum appears in JAMA 1997, 278:118]. JAMA 1997, 277:1445–1451.\nYamada AH, Lieskovsky G, Petrovich Z, et al.: Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer. Am J Clin Oncol 1994, 17:277–285.\nvan den Ouden D, Hop WC, Schroder FH: Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998, 160:1392–1397. Radical prostatectomy as monotherapy in patients with locally advanced nonmetastatic prostate cancer (T3) produces acceptable results in those with well or moderately differentiated tumors. The results of progression and survival are not significantly different from those in patients with locally confined prostate cancer. However, patients with poorly differentiated tumors (T3G3) have early progression and need adjuvant treatment after surgery.\nZincke H, Lau W, Bergstralh E, Blute ML: Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001, 166:2208–2215. Early adjuvant hormonal therapy has a significant impact on time to progression and cause-specific survival in patients with locally advanced prostate cancer after radical prostatectomy. This improvement continues to be observed, even in the very high-risk categories of seminal vesical invasion or limited lymph node metastasis.\nMorgan WR, Zincke H, Rainwater LM, et al.: Prostate-specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)[comment]. J Urol 1991, 145:319–323.\nStein A, deKernion JB, Dorey F, Smith RB: Adjuvant radiotherapy in patients post-radical prostatectomy with tumor extending through capsule or positive seminal vesicles. Urology 1992, 39:59–62.\nSchild SE, Wong WW, Grado GL, et al.: The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer [comment]. Int J Radiat Oncol Biol Phys 1996, 34:535–541. Low-dose adjuvant radiotherapy after radical prostatectomy improves freedom from recurrence rates for patients with direct local extension of the cancer. When the seminal vesicles are involved with prostate cancer, radiotherapy does not seem to alter disease outcome.\nOesterling JE, Andrews PE, Suman VJ, et al.: Preoperative androgen deprivation therapy: artificial lowering of serum prostate-specific antigen without downstaging the tumor. J Urol 1993, 149:779–782.\nVan Poppel H, De Ridder D, Elgamal AA, et al.: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial: The Belgian Uro-Oncological Study Group. J Urol 1995, 154:429–434.\nAndros EA, Danesghari F, Crawford ED: Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate. Clin Invest Med 1993, 16:510–515.\nAprikian AG, Fair WR, Reuter VE, et al.: Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br J Urol 1994, 74:630–636.\nArmas OA, Aprikian AG, Melamed J, et al.: Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994, 18:979–991.\nSassine AM, Schulman CC: Neoadjuvant hormonal deprivation before radical prostatectomy. Eur Urol 1993, 24(suppl 2):46–50.\nSchulman CC, Debruyne FM, Forster G, et al.: 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer: European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000, 38:706–713. A prospective, randomized trial of neoadjuvant hormonal therapy followed by radical prostatectomy in all patients (cT2 and cT3) with newly diagnosed prostate cancer. There is no substantial benefit received from neoadjuvant therapy in achieving complete tumor excision, decreased positive surgical margins, or a long-term disease-free interval.\nAmling CL, Blute ML, Bergstralh EJ, et al.: Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Semin Urol Oncol 1997, 15:222–229.\nPetrovich Z, Lieskovsky G, Langholz B, et al.: Comparison of outcomes of radical prostatectomy with and without adjuvant pelvic irradiation in patients with pathologic stage C (T3N0) adenocarcinoma of the prostate. Am J Clin Oncol 1999, 22:323–331. Low-dose postoperative radiotherapy is of low toxicity and it did not increase the incidence of incontinence after radical prostatectomy. In multivariate analysis, patients receiving surgery plus radiotherapy had a significantly lower rate of recurrence than patients undergoing surgery alone, especially for patients with poor prognostic factors.\nPetrovich Z, Lieskovsky G, Langholz B, et al.: Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1998, 40:139–147.\nStromberg J, Martinez A, Benson R, et al.: Improved local control and survival for surgically staged patients with locally advanced prostate cancer treated with up-front low dose rate iridium-192 prostate implantation and external beam irradiation. Int J Radiat Oncol Biol Phys 1994, 28:67–75.\nZincke H: Combined surgery and immediate adjuvant hormonal treatment for stage D1 adenocarcinoma of the prostate: Mayo Clinic experience. Semin Urol 1990, 8:175–183.\nZincke H, Utz DC, Thule PM, Taylor WF: Treatment options for patients with stage D1 (T0-3,N1-2,M0) adenocarcinoma of prostate. Urology 1987, 30:307–315.\nIocca A, Zincke H: Management of clinical T3 prostate cancer. AUA Update Series 1999, 18:250–255.",{"EN":221},"The proper management of patients with locally advanced adenocarcinoma of the prostate has been contentious and too frequently based on antiquated misconceptions. Nonextirpative treatments, even when combined with neoadjuvant hormonal therapy, are inferior to the surgical removal of the prostate for controlling local progression and distant dissemination of the cancer. Radical prostatectomy combined with early adjunctive hormonal therapy for patients with nodal metastasis is superior to all other forms of therapy and should be considered the standard of care. This approach provides survival rates comparable with patients with clinically organ-confined prostate cancer.",{"EN":223},"Radical prostatectomy for the patient with locally advanced prostate cancer",{"VOID":225},"10.1007\u002Fs11918-003-0002-5","VERIFIED","Auto Verify","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11918-003-0002-5",[230,245],{"id":231,"sortIndex":56,"researcher":20,"roles":232,"affiliations":233,"properties":242},"59bdf146-b3fd-424c-9e95-07a3e9fe11f4",[87],[234],{"id":20,"sortIndex":21,"affiliation":235,"properties":20},{"id":236,"createTime":237,"updateTime":237,"relativeEntities":238,"slug":20,"properties":239,"entityType":107,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"d3487b36-606d-4df6-80a6-5f683dd0480e","2023-12-24T05:16:50.214+00:00",[],{"title":240},{"VI":241},"Department of Urology, Mayo Clinic, Rochester, USA",{"title":243},{"VI":244},"Horst Zincke",{"id":246,"sortIndex":21,"researcher":20,"roles":247,"affiliations":248,"properties":254},"f668e037-a38a-4967-bd8b-e9604de9d82b",[87],[249],{"id":20,"sortIndex":21,"affiliation":250,"properties":20},{"id":236,"createTime":237,"updateTime":237,"relativeEntities":251,"slug":20,"properties":252,"entityType":107,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":253},{"VI":241},{"title":255},{"VI":256},"John F. Ward",{"url":228,"publisher":258,"properties":278},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":259,"slug":10,"properties":260,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":264,"manageAffiliations":265,"indexDatabases":266,"url":20,"thumbnailPath":20,"statistic":273,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":261,"eissn":262,"title":263},{"VOID":13},{"VOID":15},{"EN":17},[],[],[267],{"id":26,"indexDatabase":268,"url":39,"indexYears":40,"academicFieldIds":20,"indexDatabaseRanking":41},{"id":28,"createTime":29,"updateTime":30,"relativeEntities":269,"label":270,"description":271,"key":36,"publicationTags":272,"standard":20},[],{"EN":33,"VI":33},{"EN":33,"VI":35},[38],{"impactFactor":21,"impactFactorByYear":274,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":44,"totalPublicationByYear":275,"totalCitation":52,"totalCitationByYear":276,"totalCitationPerPublication":57,"totalCitationPerPublicationByYear":277,"hindexLast5Year":55,"hindex":55},{},{"2003":46,"2004":47,"2005":48,"2006":48,"2007":49,"2008":50,"2009":51},{"2004":54,"2006":55,"2008":56},{"2004":59,"2006":60,"2008":57},{"volume":279,"pages":281},{"VOID":280},"1",{"VOID":282},"5-13","2003-07-01",2003,{"id":286,"createTime":287,"updateTime":287,"relativeEntities":288,"slug":289,"properties":290,"entityType":80,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":299,"translateLanguages":20,"viewCount":21,"primaryUrl":301,"fullTextUrl":20,"authors":302,"publicationType":114,"publisherRelationship":332,"citationCount":55,"citationInfo":353,"publishDate":355,"publishYear":356,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":357,"isForceReanalyzing":143},"c944ce7f-9e1e-468f-b593-6e3e0ec5b5ac","2024-04-14T23:15:58.039+00:00",[],"Management-of-the-complications-of-external-beam-radiotherapy-and-brachytherapy",{"keywords":291,"openalex":292,"abstract":294,"title":295,"doi":297},{},{"VOID":293},"W4232703518",{},{"EN":296},"Management of the complications of external beam radiotherapy and brachytherapy",{"VOID":298},"10.1007\u002Fs11918-006-0017-9",[300],"EN","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11918-006-0017-9",[303,314],{"id":304,"sortIndex":21,"researcher":20,"roles":305,"affiliations":306,"properties":307},"d75e7d0f-ebb1-4a91-978f-3662e44b5c3a",[],[],{"openalex":308,"orcid":310,"title":312},{"VOID":309},"A5031483568",{"VOID":311},"https:\u002F\u002Forcid.org\u002F0000-0003-3933-9207",{"EN":313},"Stacy Loeb",{"id":315,"sortIndex":56,"researcher":20,"roles":316,"affiliations":317,"properties":327},"5e7b2cd9-c588-43fd-a0a6-6ec1674e18cc",[],[318],{"id":20,"sortIndex":21,"affiliation":319,"properties":20},{"id":320,"createTime":321,"updateTime":321,"relativeEntities":322,"slug":323,"properties":324,"entityType":107,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"ff9522a6-70d0-42e0-8261-406548020ea7","2024-04-14T23:15:58.057+00:00",[],"Northwestern-Medical-Faculty-Foundation-675-North-Saint-Clair-Street-Suite-20-150-60611-Chicago-IL-USA",{"title":325},{"EN":326},"Northwestern Medical Faculty Foundation, 675 North Saint Clair Street, Suite 20-150, 60611, Chicago, IL, USA",{"openalex":328,"title":330},{"VOID":329},"A5022422055",{"EN":331},"Robert B. Nadler",{"url":20,"publisher":333,"properties":20},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":334,"slug":10,"properties":335,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":339,"manageAffiliations":340,"indexDatabases":341,"url":20,"thumbnailPath":20,"statistic":348,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":336,"eissn":337,"title":338},{"VOID":13},{"VOID":15},{"EN":17},[],[],[342],{"id":26,"indexDatabase":343,"url":39,"indexYears":40,"academicFieldIds":20,"indexDatabaseRanking":41},{"id":28,"createTime":29,"updateTime":30,"relativeEntities":344,"label":345,"description":346,"key":36,"publicationTags":347,"standard":20},[],{"EN":33,"VI":33},{"EN":33,"VI":35},[38],{"impactFactor":21,"impactFactorByYear":349,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":44,"totalPublicationByYear":350,"totalCitation":52,"totalCitationByYear":351,"totalCitationPerPublication":57,"totalCitationPerPublicationByYear":352,"hindexLast5Year":55,"hindex":55},{},{"2003":46,"2004":47,"2005":48,"2006":48,"2007":49,"2008":50,"2009":51},{"2004":54,"2006":55,"2008":56},{"2004":59,"2006":60,"2008":57},{"total":55,"publishYear":20,"statisticByYear":354},{"2015":56,"2022":56},"2006-03-01",2006,[358,362,365,369,373,377,381,385,388,392,396,400,404,408,412,416,420,424,428,431,435,438,442,446,450,454,458,461,465,469,473,477,481,485,489,493,497,501,505,509,513,517,521,525,529,533],{"id":20,"text":359,"url":20,"identifiers":360},"Cooperberg MR, Lubeck DP, Meng MV, et al.: The changing face of low-risk prostate cancer: trends in clinical presentation and primar y management. J Clin Oncol 2004, 22:2141–2149.",{"doi":361},"10.1200\u002FJCO.2004.10.062",{"id":20,"text":363,"url":20,"identifiers":364},"Sharkey J, Chovnick SD, Behar RJ, et al.: Evolution of techniques for ultrasound-guided palladium 103 brachytherapy in 950 patients with prostate cancer. Tech Urol 2000, 6:128–134.",{},{"id":20,"text":366,"url":20,"identifiers":367},"Mate TP, Gottesman JE, Hatton J, et al.: High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 1998, 41:525–533.",{"doi":368},"10.1016\u002FS0360-3016(98)00097-2",{"id":20,"text":370,"url":20,"identifiers":371},"Slater JD, Rossi CJ Jr, Yonemoto LT, et al.: Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 2004, 59:348–352.",{"doi":372},"10.1016\u002Fj.ijrobp.2003.10.011",{"id":20,"text":374,"url":20,"identifiers":375},"Zelefsky MJ, Moughan J, Owen J, et al.: Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys 2004, 59:1053–1061.",{"doi":376},"10.1016\u002Fj.ijrobp.2003.12.011",{"id":20,"text":378,"url":20,"identifiers":379},"Kuban D, Pollack A, Huang E, et al.: Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57:1260–1268.",{"doi":380},"10.1016\u002FS0360-3016(03)00772-7",{"id":20,"text":382,"url":20,"identifiers":383},"Woel R, Beard C, Chen MH, et al.: Acute gastrointestinal, genitourinar y, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization. Int J Radiat Oncol Biol Phys 2005, 62:392–396. This recent paper from the Har vard group discusses the frequency of patient-reported radiotherapy complications requiring medical inter vention.",{"doi":384},"10.1016\u002Fj.ijrobp.2004.10.003",{"id":20,"text":386,"url":20,"identifiers":387},"Ames CD, Gray M: Voiding dysfunction after radiation to the prostate for prostate cancer. J Wound Ostomy Continence Nurs 2000, 27:155–167. This clinically oriented paper presents many helpful suggestions for improving the care and quality of life for patients with urinary problems after prostate radiation.",{},{"id":20,"text":389,"url":20,"identifiers":390},"Roach M 3rd: Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer. Urol Clin North Am 2004, 31:353–366. This review, written by a radiation oncologist specializing in prostate cancer, describes many of the common complications associated with prostate radiotherapy.",{"doi":391},"10.1016\u002Fj.ucl.2004.02.001",{"id":20,"text":393,"url":20,"identifiers":394},"Fung AY, Enke CA, Ayyangar KM, et al.: Prostate motion and isocenter adjustment from ultrasound-based localization during deliver y of radiation therapy. Int J Radiat Oncol Biol Phys 2005, 61:984–992.",{"doi":395},"10.1016\u002Fj.ijrobp.2004.07.727",{"id":20,"text":397,"url":20,"identifiers":398},"Jereczek-Fossa BA, Marsiglia HR, Orecchia R: Radiotherapyrelated fatigue. Crit Rev Oncol Hematol 2002, 41:317–325.",{"doi":399},"10.1016\u002FS1040-8428(01)00143-3",{"id":20,"text":401,"url":20,"identifiers":402},"Greenberg DB, Gray JL, Mannix CM, et al.: Treatmentrelated fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage 1993, 8:196–200.",{"doi":403},"10.1016\u002F0885-3924(93)90127-H",{"id":20,"text":405,"url":20,"identifiers":406},"Turesson I, Bernefors R, Book M, et al.: Normal tissue response to low doses of radiotherapy assessed by molecular markers: a study of skin in patients treated for prostate cancer. Acta Oncol 2001, 40:941–951.",{"doi":407},"10.1080\u002F02841860152708224",{"id":20,"text":409,"url":20,"identifiers":410},"Merrick GS, Butler WM, Wallner KE, et al.: Brachytherapyrelated dysuria. BJU Int 2005, 95:597–602.",{"doi":411},"10.1111\u002Fj.1464-410X.2005.05346.x",{"id":20,"text":413,"url":20,"identifiers":414},"Flam TA, Peyromaure M, Chauveinc L, et al.: Postbrachytherapy transurethral resection of the prostate in patients with localized prostate cancer. J Urol 2004, 172:108–111.",{"doi":415},"10.1097\u002F01.ju.0000132136.95221.63",{"id":20,"text":417,"url":20,"identifiers":418},"Kollmeier MA, Stock RG, Cesaretti J, Stone NN: Urinar y morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol 2005, 173:808–812.",{"doi":419},"10.1097\u002F01.ju.0000152698.20487.0e",{"id":20,"text":421,"url":20,"identifiers":422},"Mullokandov E, Gejerman G: Analysis of serial CT scans to assess template and catheter movement in prostate HDR brachytherapy. Int J Radiat Oncol Biol Phys 2004, 58:1063–1071.",{"doi":423},"10.1016\u002Fj.ijrobp.2003.08.020",{"id":20,"text":425,"url":20,"identifiers":426},"Di Muzio N, Longobardi B, Losa A, et al.: Seed migration in prostate brachytherapy: a re-implant case report. Br J Radiol 2003, 76:913–915.",{"doi":427},"10.1259\u002Fbjr\u002F14541259",{"id":20,"text":429,"url":20,"identifiers":430},"RTOG\u002FEORTC Late Radiation Morbidity Scoring Schema, version 2.0. http:\u002F\u002Fwww.rtog.org\u002Fmembers\u002Ftoxicity\u002Flate. html. National Institutes of Health 1999. This is the universal criteria used to describe the late complications associated with radiation therapy, and is available to the public online.",{},{"id":20,"text":432,"url":20,"identifiers":433},"Flanigan RC, Patterson J, Mendiondo OA, et al.: Complications associated with preoperative radiation therapy and Iodine-125 brachytherapy for localized prostatic carcinoma. Urology 1983, 22:123–126.",{"doi":434},"10.1016\u002F0090-4295(83)90490-9",{"id":20,"text":436,"url":20,"identifiers":437},"Hemal AK, Praveen BV, Sankaranarayanan A, Vaidyanathan S: Control of persistent vesical bleeding due to radiation cystitis by intravesical application of 15 (S) 15-methyl prostaglandin F2-alpha. Indian J Cancer 1989, 26:99–101.",{},{"id":20,"text":439,"url":20,"identifiers":440},"Miura M, Sasagawa I, Kubota Y, et al.: Effective hyperbaric oxygenation with prostaglandin E1 for radiation cystitis and colitis after pelvic radiotherapy. Int Urol Nephrol 1996, 28:643–647.",{"doi":441},"10.1007\u002FBF02552159",{"id":20,"text":443,"url":20,"identifiers":444},"Chong K T, Hampson NB, Bostwick DG, et al.: Hyperbaric oxygen does not accelerate latent in vivo prostate cancer: implications for the treatment of radiation-induced haemorrhagic cystitis. BJU Int 2004, 94:1275–1278.",{"doi":445},"10.1111\u002Fj.1464-410X.2004.05156.x",{"id":20,"text":447,"url":20,"identifiers":448},"Chong KT, Hampson NB, Corman JM: Early hyperbaric oxygen therapy improves outcome for radiationinduced hemorrhagic cystitis. Urology 2005, 65:649–653.",{"doi":449},"10.1016\u002Fj.urology.2004.10.050",{"id":20,"text":451,"url":20,"identifiers":452},"Merrick GS, Butler WM, Tollenaar BG, et al.: The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 2002, 52:461–468.",{"doi":453},"10.1016\u002FS0360-3016(01)01811-9",{"id":20,"text":455,"url":20,"identifiers":456},"Talcott JA, Manola J, Clark JA, et al.: Time course and predictors of symptoms after primar y prostate cancer therapy. J Clin Oncol 2003, 21:3979–3986. This prospective cohort study compares patient-reported GU, GI, and sexual function at 24 months following EBRT, brachytherapy, and radical prostatectomy.",{"doi":457},"10.1200\u002FJCO.2003.01.199",{"id":20,"text":459,"url":20,"identifiers":460},"Denton A, Forbes A, Andreyev J, Maher EJ: Non-surgical inter ventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database Syst Rev 2002, 1:CD003455.",{},{"id":20,"text":462,"url":20,"identifiers":463},"Dearnaley DP, Khoo VS, Norman AR, et al.: Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999, 353:267–272.",{"doi":464},"10.1016\u002FS0140-6736(98)05180-0",{"id":20,"text":466,"url":20,"identifiers":467},"Larson DW, Chrouser K, Young-Fadok T, Nelson H: Rectal complications af ter modern radiation for prostate cancer: a colorectal surgical challenge. J Gastrointest Surg 2005, 9:461–466.",{"doi":468},"10.1016\u002Fj.gassur.2005.01.295",{"id":20,"text":470,"url":20,"identifiers":471},"Theodorescu D, Gillenwater J Y, Koutrouvelis PG: Prostatourethral-rectal fistula after prostate brachytherapy. Cancer 2000, 89:2085–2091.",{"doi":472},"10.1002\u002F1097-0142(20001115)89:10\u003C2085::AID-CNCR8>3.0.CO;2-Q",{"id":20,"text":474,"url":20,"identifiers":475},"Shah SA, Cima RR, Benoit E, et al.: Rectal complications after prostate brachytherapy. Dis Colon Rectum 2004, 47:1487–1492.",{"doi":476},"10.1007\u002Fs10350-004-0603-2",{"id":20,"text":478,"url":20,"identifiers":479},"Chrouser KL, Leibovich BC, Sweat SD, et al.: Urinar y fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol 2005, 173:1953–1957. A recent article targeted at urologists, discussing the evaluation and surgical management of rectourethral and other fistulas following prostate radiotherapy.",{"doi":480},"10.1097\u002F01.ju.0000158041.77063.ff",{"id":20,"text":482,"url":20,"identifiers":483},"Chinn DM, Holland J, Crownover RL, Roach M 3rd: Potency following high-dose three-dimensional conformal radiotherapy and the impact of prior major urologic surgical procedures in patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 1995, 33:15–22.",{"doi":484},"10.1016\u002F0360-3016(95)97508-X",{"id":20,"text":486,"url":20,"identifiers":487},"Potosky AL, Davis W W, Hoffman RM, et al.: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004, 96:1358–1367.",{"doi":488},"10.1093\u002Fjnci\u002Fdjh259",{"id":20,"text":490,"url":20,"identifiers":491},"Grills IS, Martinez A A, Hollander M, et al.: High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004, 171:1098–1104.",{"doi":492},"10.1097\u002F01.ju.0000113299.34404.22",{"id":20,"text":494,"url":20,"identifiers":495},"Zelefsky MJ, Eid JF: Elucidating the etiolog y of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys 1998, 40:129–133.",{"doi":496},"10.1016\u002FS0360-3016(97)00554-3",{"id":20,"text":498,"url":20,"identifiers":499},"Zelefsky MJ, McKee AB, Lee H, Leibel SA: Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology 1999, 53:775–778.",{"doi":500},"10.1016\u002FS0090-4295(98)00594-9",{"id":20,"text":502,"url":20,"identifiers":503},"McKenzie M, MacLennan I, Kostashuk E, Bainbridge T: Postirradiation sarcoma after external beam radiation therapy for localized adenocarcinoma of the prostate: report of three cases. Urology 1999, 53:1228.",{"doi":504},"10.1016\u002FS0090-4295(98)00477-4",{"id":20,"text":506,"url":20,"identifiers":507},"Amendola BE, Amendola MA, McClatchey KD, Miller CH Jr: Radiation-associated sarcoma: a review of 23 patients with postradiation sarcoma over a 50-year period. Am J Clin Oncol 1989, 12:411–415.",{"doi":508},"10.1097\u002F00000421-198910000-00010",{"id":20,"text":510,"url":20,"identifiers":511},"Brenner DJ, Curtis RE, Hall EJ, Ron E: Second malignancies in prostate carcinoma patients after radiotherapy compared with surger y. Cancer 2000, 88:398–406.",{"doi":512},"10.1002\u002F(SICI)1097-0142(20000115)88:2\u003C398::AID-CNCR22>3.0.CO;2-V",{"id":20,"text":514,"url":20,"identifiers":515},"Johnstone PA, Powell CR, Riffenburgh R, et al.: Second primar y malignancies in T1-3N0 prostate cancer patients treated with radiation therapy with 10-year follow-up. J Urol 1998, 159:946–949.",{"doi":516},"10.1016\u002FS0022-5347(01)63777-7",{"id":20,"text":518,"url":20,"identifiers":519},"Movsas B, Hanlon AL, Pinover W, Hanks GE: Is there an increased risk of second primaries following prostate irradiation? Int J Radiat Oncol Biol Phys 1998, 41:251–255.",{"doi":520},"10.1016\u002FS0360-3016(97)00570-1",{"id":20,"text":522,"url":20,"identifiers":523},"Lowe BA, Stamey TA: Endoscopic topical placement of formalin soaked pledgets to control localized hemorrhage due to radiation cystitis. J Urol 1997, 158:528–529.",{"doi":524},"10.1016\u002FS0022-5347(01)64527-0",{"id":20,"text":526,"url":20,"identifiers":527},"Pyeritz RE, Droller MJ, Bender WL, Saral R: An approach to the control of massive hemorrhage in cyclophosphamideinduced cystitis by intravenous vasopressin: a case report. J Urol 1978, 120:253–254.",{"doi":528},"10.1016\u002FS0022-5347(17)57129-3",{"id":20,"text":530,"url":20,"identifiers":531},"Lojanapiwat B, Sripralakrit S, Soonthornphan S, Wudhikarn S: Intravesical formalin instillation with a modified technique for controlling haemorrhage secondary to radiation cystitis. Asian J Surg 2002, 25:232–235.",{"doi":532},"10.1016\u002FS1015-9584(09)60181-0",{"id":20,"text":534,"url":20,"identifiers":535},"Barry MJ, Fowler FJ Jr, O’Leary MP, et al.: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992, 148:1549–1557; discussion 1564.",{"doi":536},"10.1016\u002FS0022-5347(17)36966-5",{"id":538,"createTime":539,"updateTime":540,"relativeEntities":541,"slug":542,"properties":543,"entityType":80,"verifyStatus":226,"verifyTime":540,"verifyNote":227,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":552,"fullTextUrl":20,"authors":553,"publicationType":114,"publisherRelationship":569,"citationCount":20,"citationInfo":20,"publishDate":595,"publishYear":596,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":143},"377e1335-b83d-460e-ae10-f228e7e6fc66","2024-01-01T15:14:57.454+00:00","2025-02-14T23:09:53.194+00:00",[],"What-is-the-pathologist-saying-Interpretation-of-the-prostate-pathology-report",{"references":544,"abstract":546,"title":548,"doi":550},{"VOID":545},"Amin M, Boccon-Gibod L, Egevad L, et al.: Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl 2005, 216:20–33.\nEpstein JI, Srigley J, Grignon D, Humphrey P: Recommendations for the reporting of prostate carcinoma: Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol 2008, 129:24–30.\nSrigley JR, Amin MB, Epstein JI, et al.: Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland. Arch Pathol Lab Med 2006, 130:936–946.\nEpstein JI, Allsbrook WCJ, Amin MB, Egevad LL: The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005, 29:1228–1242.\nHeffner DK: Pathologists are from Mercury, clinicians are from Uranus: the perverted prospects for perceptual pathology. Ann Diagn Pathol 2008, 12:304–309.\nPowsner SM, Costa J, Homer RJ: Clinicians are from Mars and pathologists are from Venus. Arch Pathol Lab Med 2000, 124:1040–1046.\nHameed O, Humphrey PA: Immunohistochemical evaluation of prostate needle biopsies using saved interval sections vs. new recut sections from the block: a prospective comparison. Am J Clin Pathol 2009, 131:683–687.\nViglione MP, Potter S, Epstein JI: Should BPH be diagnosed on prostate needle biopsy? Mod Pathol 2001, 14:739.\nNadler RB, Humphrey PA, Smith DS, et al.: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995, 154:407–413.\nOppenheimer JR, Kahane H, Epstein JI: Granulomatous prostatitis on needle biopsy. Arch Pathol Lab Med 1997, 121:724–729.\nPostma R, Schroder FH, van der Kwast TH: Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men. Urology 2005, 65:745–749.\nAyala AG, Ro JY: Prostatic intraepithelial neoplasia: recent advances. Arch Pathol Lab Med 2007, 131:1257–1266.\nGodoy G, Taneja SS: Contemporary clinical management of isolated high-grade prostatic intraepithelial neoplasia. Prostate Cancer Prostatic Dis 2008, 11:20–31.\nAkhavan A, Keith JD, Bastacky SI, et al.: The proportion of cores with high-grade prostatic intraepithelial neoplasia on extended-pattern needle biopsy is significantly associated with prostate cancer on site-directed repeat biopsy. BJU Int 2007, 99:765–769.\nEpstein JI, Potter SR: The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J Urol 2001, 166:402–410.\nIczkowski KA: Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. Arch Pathol Lab Med 2006, 130:835–843.\nAllen EA, Kahane H, Epstein JI: Long-term follow-up of men with an initial atypical prostate needle biopsy. Lab Invest 2001, 81:577.\nHameed O, Humphrey PA: Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 2005, 22:88–104.\nHameed O, Humphrey PA: Immunohistochemistry in the diagnosis of minimal prostate cancer. Curr Diagn Pathol 2006, 12:279–291.\nKirby RS, Pool JL: Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br J Urol 1997, 80:521–532.\nKeoghane SR, Cranston DW: A critical overview on the role of the Nd:YAG laser in the treatment of benign prostatic hypertrophy. Eur Urol 1994, 26:193–196.\nWalsh PC, Epstein JI, Lowe FC: Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. J Urol 1987, 138:823–827.\nHodge KK, McNeal JE, Terris MK, Stamey TA: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989, 142:71–74.\nThorson P, Humphrey PA: Minimal adenocarcinoma in prostate needle biopsy tissue. Am J Clin Pathol 2000, 114:896–909.\nRubin MA, Dunn R, Kambham N, et al.: Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy? Am J Surg Pathol 2000, 24:1634–1640.\nCina SJ, Epstein JI: Adenocarcinoma of the prostate with atrophic features. Am J Surg Pathol 1997, 21:289–295.\nTran TT, Sengupta E, Yang XJ: Prostatic foamy gland carcinoma with aggressive behavior: clinicopathologic, immunohistochemical, and ultrastructural analysis. Am J Surg Pathol 2001, 25:618–623.\nHumphrey PA, Kaleem Z, Swanson PE, Vollmer RT: Pseudohyperplastic prostatic adenocarcinoma. Am J Surg Pathol 1998, 22:1239–1246.\nPapandreou CN, Daliani DD, Thall PF, et al.: Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002, 20:3072–3080.\nAmin MB, Grignon DJ, Humphrey PA, Srigley JR: Gleason Grading of Prostate Cancer: A Contemporary Approach. Philadelphia: Lippincott Williams & Wilkins; 2004.\nRuijter ET, van de Kaa CA, Schalken JA, et al.: Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 1996, 180:295–299.\nPan CC, Potter SR, Partin AW, Epstein JI: The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol 2000, 24:563–569.\nMosse CA, Magi-Galluzzi C, Tsuzuki T, Epstein JI: The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens. Am J Surg Pathol 2004, 28:394–398.\nGleason DF: Histologic grading of prostatic carcinoma. In Pathology of the Prostate. Edited by Bostwick DG. New York: Churchill Livingstone; 1990:91–92.\nGreene FL, American Joint Committee on Cancer, American Cancer Society: AJCC Cancer Staging Manual. New York: Springer-Verlag; 2002:421.\nEpstein JI, Netto GJ: Biopsy Interpretation of the Prostate, edn 4. Philadelphia: Lippincott Williams & Wilkins; 2007.\nShariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW: An updated catalog of prostate cancer predictive tools. Cancer 2008, 113:3075–3099.\nBrimo F, Vollmer RT, Corcos J, et al.: Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology 2008, 53:177–183.\nBismar TA, Lewis JS Jr, Vollmer RT, Humphrey PA: Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. Am J Surg Pathol 2003, 27:432–440.\nHumphrey PA, Vollmer RT: Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 1997, 10:326–333.\nCheng L, Koch MO, Juliar BE, et al.: The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol 2005, 23:2911–2917.\nStamey TA, McNeal JE, Yemoto CM, et al.: Biological determinants of cancer progression in men with prostate cancer. JAMA 1999, 281:1395–1400.\nde la Taille A, Rubin MA, Buttyan R, et al.: Is microvascular invasion on radical prostatectomy specimens a useful predictor of PSA recurrence for prostate cancer patients? Eur Urol 2000, 38:79–84.\nChuang AY, Nielsen ME, Hernandez DJ, et al.: The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy. J Urol 2007, 178:1306–1310.\nCheng L, Bergstralh EJ, Cheville JC, et al.: Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 1998, 22:1491–1500.\nBoormans JL, Wildhagen MF, Bangma CH, et al.: Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer. BJU Int 2008, 102:1589–1593.",{"EN":547},"Management of patients presenting with elevated serum prostate-specific antigen levels, or those with previously diagnosed prostate carcinoma, is very much dependent on the pathology report on needle biopsy or radical prostatectomy specimens obtained from these patients. In contrast to a diagnosis of benignity or high-grade prostatic intraepithelial neoplasia, a diagnosis of atypia on needle core biopsy is usually an indication for a repeat biopsy; however, it is important to understand that atypia and other related terms are not specific diagnoses. The pathology report on different prostate specimens with a diagnosis of carcinoma usually includes the Gleason grade and extent of carcinoma, among other morphological prognostic and predictive factors. Understanding the significance of these morphological factors and how they are evaluated and incorporated into the pathology report, as well as newer developments in this field, can assist urologists in the interpretation of the pathological findings and ultimately lead to better clinical care.",{"EN":549},"What is the pathologist saying? Interpretation of the prostate pathology report",{"VOID":551},"10.1007\u002Fs11918-009-0020-z","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11918-009-0020-z",[554],{"id":555,"sortIndex":21,"researcher":20,"roles":556,"affiliations":557,"properties":566},"88bac98d-72fc-4f95-a88c-50968ce021d9",[87],[558],{"id":20,"sortIndex":21,"affiliation":559,"properties":20},{"id":560,"createTime":561,"updateTime":561,"relativeEntities":562,"slug":20,"properties":563,"entityType":107,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"d7daafdc-3479-45d3-8f50-1928558a56c1","2024-01-01T15:14:57.463+00:00",[],{"title":564},{"VI":565},"Departments of Pathology and Surgery, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, USA",{"title":567},{"VI":568},"Omar Hameed",{"url":552,"publisher":570,"properties":590},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":571,"slug":10,"properties":572,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":576,"manageAffiliations":577,"indexDatabases":578,"url":20,"thumbnailPath":20,"statistic":585,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":573,"eissn":574,"title":575},{"VOID":13},{"VOID":15},{"EN":17},[],[],[579],{"id":26,"indexDatabase":580,"url":39,"indexYears":40,"academicFieldIds":20,"indexDatabaseRanking":41},{"id":28,"createTime":29,"updateTime":30,"relativeEntities":581,"label":582,"description":583,"key":36,"publicationTags":584,"standard":20},[],{"EN":33,"VI":33},{"EN":33,"VI":35},[38],{"impactFactor":21,"impactFactorByYear":586,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":44,"totalPublicationByYear":587,"totalCitation":52,"totalCitationByYear":588,"totalCitationPerPublication":57,"totalCitationPerPublicationByYear":589,"hindexLast5Year":55,"hindex":55},{},{"2003":46,"2004":47,"2005":48,"2006":48,"2007":49,"2008":50,"2009":51},{"2004":54,"2006":55,"2008":56},{"2004":59,"2006":60,"2008":57},{"volume":591,"pages":593},{"VOID":592},"7",{"VOID":594},"141-147","2009-11-24",2009,{"id":598,"createTime":599,"updateTime":599,"relativeEntities":600,"slug":20,"properties":601,"entityType":80,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":610,"fullTextUrl":20,"authors":611,"publicationType":114,"publisherRelationship":634,"citationCount":20,"citationInfo":20,"publishDate":659,"publishYear":142,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":143},"6fe87742-f5d4-40d0-bf27-eabee2b6426a","2024-02-21T23:03:43.494+00:00",[],{"references":602,"abstract":604,"title":606,"doi":608},{"VOID":603},"Collins MM, Stafford RS, O’Leary MP, Barry MJ: How common is prostatitis? A national survey of physician visits. J Urol 1998, 159:1224–1228.\nRizzo M, Marchetti F, et al.: Clinical characterization of the prostatitis patient in Italy: a prospective urology outpatient study. World J Urol 2005, 23:61–66.\nRoberts RO, Jacobson DJ, Girman CJ, et al.: Prevalence of prostatitis-like symptoms in a community based cohort of older men. J Urol 2002, 168:2467–2471.\nNickel JC, Downey J, Hunter D, Clark J: Prevalence of prostatitis-like symptoms in a population-based study using the National Institutes of Health Chronic Prostatitis Symptom Index. J Urol 2001, 165:842–845.\nKrieger JN, Nyberg L, Nickel JC: NIH Consensus definition and classification of prostatitis. JAMA 1999, 282:236–237.\nNickel JC: Recommendations for the evaluation of patients with prostatitis. World J Urol 2003, 21:75–81.\nMillan-Rodriguez F, Palou J, Bujons-Tur A, et al.: Acute bacterial prostatitis: two different subcategories according to a previous manipulation of the lower urinary tract. World J Urol 2006, 24:45–50.\nNickel JC, Moon T: Chronic bacterial prostatitis: an evolving clinical enigma. Urology 2005, 66:2–8.\nSchaeffer AJ, Datta NS, Jackson EF, et al.: Overview summary statement. Urology 2002, 60:1–4.\nPontari MA: Prostatitis. In Conn’s Current Therapy 2006. Edited by Rakel RE, Bope ET. Philadelphia: Elsevier; 2006:863–865.\nNickel JC: Classification and diagnosis of prostatitis: a gold standard? Andrologia 2003, 35:160–167.\nLitwin MS, McNaughton-Collins M, Fowler FJ, et al.: The National Institutes of Health Chronic Prostatitis Symptoms Index: development and validation of a new outcome measure. J Urol 1999, 162:369.\nRoberts RO, Jacobson DJ, Girman CJ, et al.: Low agreement between previous physician diagnosed prostatitis and National Institutes of Health Chronic Prostatitis Symptom Index Pain Measures. J Urol 2004, 171:279–283.\nNickel JC, Ardern D, Downey J: Cytologic evaluation of urine is important in evaluation of chronic prostatitis. Urology 2002, 60:225–227.\nMeares E, Stamey T: Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968, 5:492–518.\nMcNaughton-Collins M, Fowler FF, Elliot DB, et al.: Diagnosing and treating chronic prostatitis: do urologists use the four-glass test? Urology 2000, 55:403–407.\nNickel JC: The pre-and post-massage test (PPMT): a simple screen for prostatitis. Tech Urol 1997, 3:38–43.\nLudwig M, Schroeder-Printzen I, Ludecke G, Weidner W: Comparison of expressed prostatic secretions with urine after prostatic massage: a means to diagnose chronic prostatitis\u002Finflammatory chronic pelvic pain syndrome. Urology 2000, 55:175–177.\nSchaeffer AJ, Knauss JS, Landis JR, et al.: Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study. J Urol 2002, 168:1048–1053.\nKaplan SA, Te AE, Jacobs BZ: Urodynamic evidence of vesical neck obstruction in men with misdiagnosed chronic nonbacterial prostatitis and the therapeutic role of endoscopic incision of the bladder neck. J Urol 1994, 152:2063–2065.\nKaplan SA, Santarosa RP, D’Alisera PM, et al.: Pseudodyssynergia (contraction of the external sphincter during voiding) misdiagnosed as chronic nonbacterial prostatitis and the role of biofeedback as a therapeutic option. J Urol 1997, 157:2234–2237.\nKaplan SA, Ikeguchi EF, Santarosa RP, et al.: Etiology of voiding dysfunction in men less than 50 years of age. Urology 1996, 47:836–839.\nCarver BS, Bozeman CB, Williams BJ, Venable DD: The prevalence of men with National Institutes of Health Category IV prostatitis and association with serum prostate-specific antigen. J Urol 2003, 169:589–591.\nKrieger JN, Ross SO, Riley DE: Chronic prostatitis: epidemiology and role of infection. Urology 2002, 60:8–12.\nShukla-Dave A, Hricak H, Eberhardt SC, et al.: Chronic prostatitis: MR imaging and H MR spectroscopic imaging findings: initial observation. Radiology 2004, 231:717–724.\nLudwig M, Vidal A, Diemer T, et al.: Chronic prostatitis\u002Fchronic pelvic pain syndrome: seminal markers of inflammation. World J Urol 2003, 21:82–85.\nOrhan I, Onur R, Ilhan N, Ardicoglu A: Seminal plasma cytokine levels in the diagnosis of chronic pelvic pain syndrome. Int J Urol 2001, 8:495–499.",{"EN":605},"Prostatitis accounts for almost 2 million office visits to urologists and primary care physicians. The label “prostatitis” refers to a diverse constellation of symptoms and disease processes. The diagnosis and treatment of this disorder present numerous challenges for the physician, including a lack of abnormal findings on physical examination, laboratory tests, and radiographic images. In this article, we offer a review of the current literature and recommendations for the evaluation and diagnosis of the patient presenting with prostatitis.",{"EN":607},"Prostatitis: Updates on diagnostic evaluation",{"VOID":609},"10.1007\u002Fs11918-007-0025-4","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11918-007-0025-4",[612,619],{"id":613,"sortIndex":21,"researcher":20,"roles":614,"affiliations":615,"properties":616},"5f04c0ee-3428-4158-84f7-2196cba07e7c",[87],[],{"title":617},{"VI":618},"Jason R. Rothman",{"id":620,"sortIndex":56,"researcher":20,"roles":621,"affiliations":622,"properties":631},"af5e28ef-e4eb-4e0c-ac6a-44b7669b3593",[87],[623],{"id":20,"sortIndex":21,"affiliation":624,"properties":20},{"id":625,"createTime":626,"updateTime":626,"relativeEntities":627,"slug":20,"properties":628,"entityType":107,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"ea9ce736-9277-4e37-9e74-272c0ad09387","2024-01-19T14:23:49.613+00:00",[],{"title":629},{"VI":630},"Department of Urology, Temple University, Philadelphia, USA",{"title":632},{"VI":633},"William I. Jaffe",{"url":610,"publisher":635,"properties":655},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":636,"slug":10,"properties":637,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":641,"manageAffiliations":642,"indexDatabases":643,"url":20,"thumbnailPath":20,"statistic":650,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":638,"eissn":639,"title":640},{"VOID":13},{"VOID":15},{"EN":17},[],[],[644],{"id":26,"indexDatabase":645,"url":39,"indexYears":40,"academicFieldIds":20,"indexDatabaseRanking":41},{"id":28,"createTime":29,"updateTime":30,"relativeEntities":646,"label":647,"description":648,"key":36,"publicationTags":649,"standard":20},[],{"EN":33,"VI":33},{"EN":33,"VI":35},[38],{"impactFactor":21,"impactFactorByYear":651,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":44,"totalPublicationByYear":652,"totalCitation":52,"totalCitationByYear":653,"totalCitationPerPublication":57,"totalCitationPerPublicationByYear":654,"hindexLast5Year":55,"hindex":55},{},{"2003":46,"2004":47,"2005":48,"2006":48,"2007":49,"2008":50,"2009":51},{"2004":54,"2006":55,"2008":56},{"2004":59,"2006":60,"2008":57},{"volume":656,"pages":657},{"VOID":138},{"VOID":658},"185-190","2007-11-07",{"id":661,"createTime":662,"updateTime":663,"relativeEntities":664,"slug":665,"properties":666,"entityType":80,"verifyStatus":19,"verifyTime":663,"verifyNote":81,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":671,"fullTextUrl":20,"authors":672,"publicationType":114,"publisherRelationship":680,"citationCount":20,"citationInfo":20,"publishDate":705,"publishYear":596,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":143},"9136b4d0-31a4-4641-a91b-2fce582d7d92","2024-01-09T16:45:19.484+00:00","2025-02-06T22:30:27.802+00:00",[],"Phosphodiesterase-type-5-inhibitors-for-the-treatment-of-female-sexual-function",{"title":667,"doi":669},{"EN":668},"Phosphodiesterase type 5 inhibitors for the treatment of female sexual function",{"VOID":670},"10.1007\u002Fs11918-009-0001-2","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11918-009-0001-2",[673],{"id":674,"sortIndex":21,"researcher":20,"roles":675,"affiliations":676,"properties":677},"57dc6868-f03d-4182-a68e-7a8d711f1de6",[87],[],{"title":678},{"VI":679},"Kevin T. McVary",{"url":671,"publisher":681,"properties":701},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":682,"slug":10,"properties":683,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":687,"manageAffiliations":688,"indexDatabases":689,"url":20,"thumbnailPath":20,"statistic":696,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":684,"eissn":685,"title":686},{"VOID":13},{"VOID":15},{"EN":17},[],[],[690],{"id":26,"indexDatabase":691,"url":39,"indexYears":40,"academicFieldIds":20,"indexDatabaseRanking":41},{"id":28,"createTime":29,"updateTime":30,"relativeEntities":692,"label":693,"description":694,"key":36,"publicationTags":695,"standard":20},[],{"EN":33,"VI":33},{"EN":33,"VI":35},[38],{"impactFactor":21,"impactFactorByYear":697,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":44,"totalPublicationByYear":698,"totalCitation":52,"totalCitationByYear":699,"totalCitationPerPublication":57,"totalCitationPerPublicationByYear":700,"hindexLast5Year":55,"hindex":55},{},{"2003":46,"2004":47,"2005":48,"2006":48,"2007":49,"2008":50,"2009":51},{"2004":54,"2006":55,"2008":56},{"2004":59,"2006":60,"2008":57},{"volume":702,"pages":703},{"VOID":592},{"VOID":704},"1-2","2009-02-10",{"id":707,"createTime":708,"updateTime":709,"relativeEntities":710,"slug":711,"properties":712,"entityType":80,"verifyStatus":226,"verifyTime":709,"verifyNote":227,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":721,"fullTextUrl":20,"authors":722,"publicationType":114,"publisherRelationship":738,"citationCount":20,"citationInfo":20,"publishDate":763,"publishYear":210,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":143},"6df4fe93-bb18-4b30-8aaf-d85d2b168c55","2024-01-18T08:23:07.167+00:00","2024-12-17T22:13:24.222+00:00",[],"Male-chronic-pelvic-pain-syndrome-Prevalence-risk-factors-treatment-patterns-and-socioeconomic-impact",{"references":713,"abstract":715,"title":717,"doi":719},{"VOID":714},"Krieger JN, Nyberg L Jr, Nickel JC: NIH consensus definition and classification of prostatitis. JAMA 1999, 282:236–237.\nCollins MM, Stafford RS, O’Leary MP, Barry MJ: How common is prostatitis? A national survey of physician visits. J Urol 1998, 159:1224–1228.\nBartoletti R, Cai T, Mondaini N, et al.: Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis\u002Fchronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. J Urol 2007, 178:2411–2415.\nLitwin MS, McNaughton-Collins M, Fowler FJ Jr, et al.: The National Institutes of Health chronic prostatitis symptom index: development and validation of a new measure. J Urol 1999, 162:369–375.\nClemens JQ, Meenan RT, O’Keeffe Rosetti MC, et al.: Incidence and clinical characteristics of National Institutes of Health type III prostatitis in the community. J Urol 2005, 174:2319–2322.\nMcNeal JE: Regional morphology and pathology of the prostate. Am J Clin Pathol 1968, 49:346–357.\nCollins MM, Meigs JB, Barry MJ, et al.: Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol 2002, 167:1363–1366.\nMehik A, Hellstrom P, Lukkarinen O, et al.: Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. BJU Int 2000, 86:443–448.\nCheah PY, Liong ML, Yuen KH, et al.: Chronic prostatitis: symptom survey with follow-up clinical evaluation. Urology 2003, 61:60–64.\nNickel JC, Downey J, Hunter D, Clark J: Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol 2001, 165:842–845.\nRoberts RO, Jacobson DJ, Girman CJ, et al.: Prevalence of prostatitis-like symptoms in a community based cohort of older men. J Urol 2002, 168:2467–2471.\nClemens JQ, Meenan RT, O’Keeffe Rosetti MC, et al.: Prevalence of prostatitis-like symptoms in a managed care population. J Urol 2006, 176:593–596.\nMarszalek M, Wehrberger C, Hochreiter W, et al.: Symptoms suggestive of chronic pelvic pain syndrome in an urban population: prevalence and associations with lower urinary tract symptoms and erectile function. J Urol 2007, 177:1815–1819.\nClemens JQ, Meenan RT, O’Keeffe Rosetti MC, et al.: Prevalence of and risk factors for prostatitis: population-based assessment using physician-assigned diagnoses. J Urol 2007, 178:1333–1337.\nRoberts RO, Lieber MM, Rhodes T, et al.: Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County study of urinary symptoms and health status among men. Urology 1998, 51:578–584.\nCollins MM, Joyce GF, Wise M, Pontari MA: Prostatitis. In Urologic Diseases in America. Edited by Litwin MS, Saigal CS. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington DC: US Government Publishing Office; 2007:11–39. [NIH Publication No. 07-5512]\nPontari MA, McNaughton-Collins M, O’Leary MP, et al.: A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int 2005, 96:559.\nHenningsen P, Zipfel S, Herzog W: Management of functional somatic syndromes. Lancet 2007, 369:946–955.\nPropert KJ, McNaughton-Collins M, Leiby BE, et al.: A prospective study of symptoms and quality of life in men with chronic prostatitis\u002Fchronic pelvic pain syndrome: the National Institutes of Health Chronic Prostatitis Cohort study. J Urol 2006, 175:619–623.\nSchaeffer AJ, Landis JR, Knauss JS, et al.: Demographic and clinical characteristics of men with chronic prostatitis: the National Institutes of Health chronic prostatitis cohort study. J Urol 2002, 168:593–598.\nClemens JQ, Meenan RT, O’Keeffe Rosetti MC, et al.: Analysis of medical costs in men diagnosed with prostatitis [abstract]. Presented at the 2006 American Urological Association Meeting. Atlanta, GA: May 20–25, 2006.\nTurner JA, Ciol MA, Von Korff M, et al.: Healthcare use and costs of primary and secondary care patients with prostatitis. Urology 2004, 63:1031–1035.\nCalhoun EA, McNaughton Collins M, Pontari MA, et al.: The economic impact of chronic prostatitis. Arch Intern Med 2004, 164:1231–1236.\nClemens JQ, Brown S, Calhoun EA: Comparison of the economic impact of chronic prostatitis\u002Fchronic pelvic pain syndrome and interstitial cystitis\u002Fpainful bladder syndrome [abstract]. Presented at the 2007 American Urological Association Meeting. Anaheim, CA; May 19–24, 2007.",{"EN":716},"Type III prostatitis (chronic prostatitis\u002Fchronic pelvic pain syndrome) is the most common form of prostatitis, accounting for 8% to 15% of urology outpatient office visits. Symptoms, including pain in the perineum, suprapubic region, testicles, or tip of the penis, are often exacerbated by urination or ejaculation. Currently available therapies have limited effectiveness in alleviating these symptoms. Further, there is an unexplained association between type III prostatitis and other unexplained somatic symptoms. Due to its high prevalence and lack of effective therapies, direct and indirect costs associated with type III prostatitis are substantial.",{"EN":718},"Male chronic pelvic pain syndrome: Prevalence, risk factors, treatment patterns, and socioeconomic impact",{"VOID":720},"10.1007\u002Fs11918-008-0013-3","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11918-008-0013-3",[723],{"id":724,"sortIndex":21,"researcher":20,"roles":725,"affiliations":726,"properties":735},"900c0192-836a-422f-bee1-3a8fd69411d1",[87],[727],{"id":20,"sortIndex":21,"affiliation":728,"properties":20},{"id":729,"createTime":730,"updateTime":730,"relativeEntities":731,"slug":20,"properties":732,"entityType":107,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"9746147d-ea55-4d29-8317-e0bbec1cb484","2023-12-26T14:03:22.715+00:00",[],{"title":733},{"VI":734},"Department of Urology, University of Michigan Medical Center, Ann Arbor, USA",{"title":736},{"VI":737},"J. Quentin Clemens",{"url":721,"publisher":739,"properties":759},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":740,"slug":10,"properties":741,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":745,"manageAffiliations":746,"indexDatabases":747,"url":20,"thumbnailPath":20,"statistic":754,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":742,"eissn":743,"title":744},{"VOID":13},{"VOID":15},{"EN":17},[],[],[748],{"id":26,"indexDatabase":749,"url":39,"indexYears":40,"academicFieldIds":20,"indexDatabaseRanking":41},{"id":28,"createTime":29,"updateTime":30,"relativeEntities":750,"label":751,"description":752,"key":36,"publicationTags":753,"standard":20},[],{"EN":33,"VI":33},{"EN":33,"VI":35},[38],{"impactFactor":21,"impactFactorByYear":755,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":44,"totalPublicationByYear":756,"totalCitation":52,"totalCitationByYear":757,"totalCitationPerPublication":57,"totalCitationPerPublicationByYear":758,"hindexLast5Year":55,"hindex":55},{},{"2003":46,"2004":47,"2005":48,"2006":48,"2007":49,"2008":50,"2009":51},{"2004":54,"2006":55,"2008":56},{"2004":59,"2006":60,"2008":57},{"volume":760,"pages":761},{"VOID":206},{"VOID":762},"81-85","2008-05-31",{"id":765,"createTime":766,"updateTime":767,"relativeEntities":768,"slug":769,"properties":770,"entityType":80,"verifyStatus":19,"verifyTime":767,"verifyNote":81,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":779,"fullTextUrl":20,"authors":780,"publicationType":114,"publisherRelationship":803,"citationCount":20,"citationInfo":20,"publishDate":829,"publishYear":830,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":143},"6d494e42-4cf5-467c-99c4-02bd3e51ac10","2023-12-20T21:35:35.198+00:00","2025-01-11T22:07:17.782+00:00",[],"Acupuncture-for-chronic-prostatitis-chronic-pelvic-pain-syndrome",{"references":771,"abstract":773,"title":775,"doi":777},{"VOID":772},"Nickel JC: Prostatitis and related conditions. In Campbell’s Urology, edn 8. Edited by Walsh PC, Retik AB, Vaughan ED Jr. Philadelphia: W.B. Saunders; 2002:603–630.\nNickel JC: The three A’s of chronic prostatitis therapy: antibiotics, alpha-blockers, and anti-inflammatories: What is the evidence? BJU Int 2004, in press.\nGun CC: Neuropathic pain: a new theory for chronic pain of intrinsic origin. Ann R Coll Physicians Surg Can 1989, 22:327–330.\nYuting C: Clinical observation on combined treatment of 360 cases of prostatitis with acupuncture of Sishenchong Point and self-drafted prescription I, II and III. World J Acupunct Moxibustion 2000, 10:1–4.\nKatai S: Effect of electric acupuncture therapy on chronic prostatitis. Bull Juntendou Univ 1992, 38:210–219.\nIkeuchi T, Iguchi H: Clinical studies on chronic prostatitis and prostatitis-like syndrome: electric acupuncture therapy for intractable cases of chronic prostatitis-like syndrome. Hinyokika Kiyo 1994, 40:587–591.\nChen C, Gao Z, Liu Y, Shen L: Treatment of chronic prostatitis with laser acupuncture. J Tradit Chin Med 1995, 15:38–41.\nGe SH, Mang FY, Xu BR: Acupuncture treatment in 102 cases of chronic prostatitis. J Tradit Chin Med 1988, 8:99–100.\nChen RC, Nickel JC: Acupuncture ameliorates symptoms in men with chronic prostatitis and chronic pelvic pain syndrome. Adult Urol 2003, 61:1156–1159.\nKrieger JN, Nyberg L, Nickel JC: NIH consensus definition and classification of prostatitis. JAMA 1999, 282:236–237.\nLitwin SM, McNaughton-Collins M, Fowler FJ, et al.: The NIH Chronic Prostatitis Symptom Index (NIH-CPSI): development and validation of a new outcomes measure. J Urol 1999, 162:369–375.\nPrice DD, Mayer DJ: Evidence for endogenous opiate analgesic mechanism and triggers by somatosensory stimulation (include acupuncture) in humans. PAIS Forum 1995, 4:40–43.\nStux G, Pomeranz B: Basics of Acupuncture, edn 4. New York: Springer; 1998.\nCheng RS, Pomeranz B: Electroacupuncture analgesia could be medicated by at least two pain-relieving mechanisms: endorphin and nonendorphin system. Life Sci 1979, 25:1957–1962.\nCheng RS: Dexamethasone partially reduces 2% saline abolishes electro acupuncture analgesic, and these finding implicate pituitary endorphin. Life SCT 1979, 24:1481–1486.\nCheng RS: Mechanism of electro acupuncture analgesic on intricate system is proposed. In PhD Thesis. Toronto: University of Toronto; 1981.\nHelms JM: Chapter II. In Acupuncture Energetics and Clinical Approach for Physicians. California: Medical Acupuncture Publisher; 1995: 31–36.\nDe Groot WC: Anatomy of the central neural pathways controlling the lower urinary tract. Eur Urol 1998, 34(suppl 1):2–5.\nHan JS, Tereniu H: Neurochemical basis of acupuncture analgesic. Annu Rev Pharmacol Toxicol 1982, 22:193–200.\nVacca-Galloway LL, Naftchi NE, Arakawa K, et al.: Alteration of immunoreactive substance P and enkephalin in rate spinal cord after electroacupuncture. Peptides 1985, 6(suppl 1):177–188.\nChang RS, Pomeranz B: A combined treatment with D-amino acids and electroacupuncture produces a greater analgesia then either treatment alone: naloxone reverses these effects. Pain 1980, 8:231–236.\nMezey E, Palkovits M, de Kloet ER, et al.: Evidence for pituitary-brain transport of a behaviorally potent ACTH analog. Life Sci 1978, 22:831–838.\nBergland RM, Page RB: Pituitary-brain vascular relations: a new paradigm. Science 1979, 204:18–24.\nTsou K, Wu SH, Wan FS, et al.: Increased levels of endorphins in the cisteral cerebrospinal fluid of rabbits in acupuncture analgesia. Act Physiologic Sinica 1979, 31:371–376.\nZermann DH, Ishigooka M, Schmidt R: Pathophysiology of the hypertonic sphincter or hyperpathic urethra. In The Urinary Sphincter. Edited by Corcos J, Schick E. New York: Marcel Dekker; 2001:201–205. This article is instructive and comprehensive. It supports the hypothesis that neuromodulatory treatments for CP\u002FCPPS could be beneficial.\nZhang ZY, Zhang K: Effect of acupuncture on the pons micturition centre and the related function of the urinary bladder. Zhen Ci Yan Jiu 1987, 12:116–122.\nPomeranz B, Cheng R: Suppression of noxious responses in single neurons of cat spinal cord by electroacupuncture and its reversal by the opiate antagonist naloxone. Exp Neurol 1979, 64:327–341.\nBasbaum AI, Fields HL: Endogenous pain control mechanism: review and hypothesis. Ann Neurol 1978, 4:451–462.\nYaksh TL, Wilson PR: Spinal serotonin terminal system medicates antinociception. J Pharmacol Exp Ther 1979, 208:446–453.\nRosenfeld JP: Interacting brain stem components of opiateactivated descending pain inhibitory system. Neurosci Biobehav Rev 1994, 18:403–409.\nYi CC, Lu TH, Wu SH, Tsou K: A study of the release of H (37 S-Hydroxytryptamine from brain during acupuncture and morphine analgesia. Sci Sin 1977, 20:113–124.\nHan CS, Shou PH, Lu CC, et al.: The role of central S-hydroxytryptamine in acupuncture analgesia. Sci Sin 1979, 22:91–104.\nEspey MJ, Du HJ, Downie JW: Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats. Brain Res 1988, 798:101–108.\nDmochowski RR, Miklos JR, Norton PA, et al.: Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003, 170:1259–1263.\nThor KB: Neurology: exploring new horizons and advanced studies. John Hopkins Med J 2002, 2:677–680.\nShoskes DA, Albakri Q, Thomas K, Cook D: Cytokine polymorphisms in men with chronic prostatitis\u002Fchronic pelvic pain syndrome: association with diagnosis and treatment response. J Urol 2002, 168:331–335. This article postulates a hypothesis that men with CP\u002FCPPS may have a genetic predisposition to inflammation or autoimmunity.\nSchmidt RA: Pelvic pain. Prob Urol 1989, 3:270–280.\nCodeere TJ, Katz J, Vaccarino A, Melzack R: Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993, 52:259–285.",{"EN":774},"Chronic prostatitis\u002Fchronic pelvic pain syndrome (CP\u002F CPPS) is prevalent in urological practice and has a significant impact on quality of life. Standard therapies often fail to achieve sustainable amelioration of symptoms. This article attempts to show that neuromodulatory treatment in the form of electroacupuncture can be a minimally invasive and effective treatment for CP\u002FCPPS that is refractory to standard therapies. This neuromodulatory therapy lends support to the hypothesis that the end stage of CP\u002FCPPS may be a neuropathic pain syndrome.",{"EN":776},"Acupuncture for chronic prostatitis\u002F chronic pelvic pain syndrome",{"VOID":778},"10.1007\u002Fs11918-004-0013-x","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11918-004-0013-x",[781,788],{"id":782,"sortIndex":56,"researcher":20,"roles":783,"affiliations":784,"properties":785},"32916f0b-135e-4a67-921f-4d9312656e88",[87],[],{"title":786},{"VI":787},"J. Curtis Nickel",{"id":789,"sortIndex":21,"researcher":20,"roles":790,"affiliations":791,"properties":800},"081ea6c8-8203-4439-9150-8b1c4687be13",[87],[792],{"id":20,"sortIndex":21,"affiliation":793,"properties":20},{"id":794,"createTime":795,"updateTime":795,"relativeEntities":796,"slug":20,"properties":797,"entityType":107,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"62c0a459-f373-4fc2-a354-67284c35ebf7","2023-12-20T21:35:35.297+00:00",[],{"title":798},{"VI":799},"King Street Medical Arts Centre, Mississauga, Canada",{"title":801},{"VI":802},"Richard C. T. Chen",{"url":779,"publisher":804,"properties":824},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":805,"slug":10,"properties":806,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":810,"manageAffiliations":811,"indexDatabases":812,"url":20,"thumbnailPath":20,"statistic":819,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":807,"eissn":808,"title":809},{"VOID":13},{"VOID":15},{"EN":17},[],[],[813],{"id":26,"indexDatabase":814,"url":39,"indexYears":40,"academicFieldIds":20,"indexDatabaseRanking":41},{"id":28,"createTime":29,"updateTime":30,"relativeEntities":815,"label":816,"description":817,"key":36,"publicationTags":818,"standard":20},[],{"EN":33,"VI":33},{"EN":33,"VI":35},[38],{"impactFactor":21,"impactFactorByYear":820,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":44,"totalPublicationByYear":821,"totalCitation":52,"totalCitationByYear":822,"totalCitationPerPublication":57,"totalCitationPerPublicationByYear":823,"hindexLast5Year":55,"hindex":55},{},{"2003":46,"2004":47,"2005":48,"2006":48,"2007":49,"2008":50,"2009":51},{"2004":54,"2006":55,"2008":56},{"2004":59,"2006":60,"2008":57},{"volume":825,"pages":827},{"VOID":826},"2",{"VOID":828},"141-144","2004-09-01",2004,{"id":832,"createTime":833,"updateTime":834,"relativeEntities":835,"slug":836,"properties":837,"entityType":80,"verifyStatus":19,"verifyTime":834,"verifyNote":81,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":846,"fullTextUrl":20,"authors":847,"publicationType":114,"publisherRelationship":870,"citationCount":20,"citationInfo":20,"publishDate":896,"publishYear":897,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":143},"531b19aa-521d-4af6-9fc9-10bc90e0108d","2023-12-28T13:49:14.751+00:00","2025-01-21T22:06:44.364+00:00",[],"Acute-urinary-retention-in-men-The-risks-and-outcomes-with-medical-therapy",{"references":838,"abstract":840,"title":842,"doi":844},{"VOID":839},"Glynn RJ, Campion EW, Bouchard GR, et al.: The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985, 121:78. The importance of this study is that it provides information about the natural history of prostatic hyperplasia at a time when medical treatment was not widely used. Because of the widespread use of 5-α reductase inhibitors and α-blockers, it would be difficult or impossible to reproduce this dataset today.\nHargreave TB, Botto H, Rikken GH, et al.: European collaborative study of antibiotic prophylaxis for transurethral resection of the prostate Eur Urol 1993, 23:437–443.\nRobinson MR, Cross RJ, Shetty MB, Fittall B: Bacteriaemia and bacteriogenic shock in district hospital urological practice. Br J Urol 1980, 52:10–14.\nMurphy DM, Falkiner FR, Carr M, et al.: Septicemia after transurethral prostatectomy. Urology 1983, 22:133–135.\nPickard R, Emberton M, Neal DE: The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol 1998, 81:712–720. The importance of this study is that it was a properly funded audit of prostate surgery from regions in the UK and included large numbers of men; the results thus reflect the standard of care in a situation in which most of the population attends one health care provider—the UK National Health Service.\nMcNeill SA, Hargreave TB: Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. J Urol 2004, 171:2316–2320. The importance of this study is that it has adequate power because of larger numbers. This is very difficult to achieve in the context of emergency treatment because of the variety of different practitioners and hospitals that deal with AUR.\nWarren JW, Tenney JH, Hoopes JM, et al.: A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis 1982, 146:719–723.\nWarren JW: Nosocomial urinary tract infections. In Principles and Practice of Infectious Diseases, edn 4. Edited by Mandell GL, Bennett JE, Dolin R. New York: Churchill Livingstone; 1995:2607–2616.\nGrabe M, Forsgren A, Hellsten S: The effect of a short antibiotic course in transurethral prostatic resection. Scand J Urol Nephrol 1984, 18:37–42.\nCafferkey MT, Conneely B, Falkiner FR, et al.: Postoperative urinary infection and septicaemia in urology. J Hosp Infect 1980, 1:315–320.\nKhoubehi B, Watkin NA, Mee AD, Ogden CW: Morbidity and the impact on daily activities associated with catheter drainage after acute urinary retention. BJU Int 2000, 85:1033–1036.\nMustonen S, Ala-Houhala IO, Tammela TL: Long-term renal dysfunction in patients with acute urinary retention. Scand J Urol Nephrol 2001, 35:44–48.\nRoehrborn CG, Malice M, Cook TJ, Girman CJ: Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001, 58:210–216. This pooled analysis is important because of the large numbers of men included, thus reducing bias.\nChan JE, Kapoor A: Herpes zoster infection: a rare cause of acute urinary retention. Can J Urol 2003, 10:1912–1913.\nAcheson J, Mudd D: Acute urinary retention attributable to sacral herpes zoster. Emerg Med J 2004, 21:752–753.\nHolm NR, Horn T, Smedts F, et al.: Does ultrastructural morphology of human detrusor smooth muscle cells characterize acute urinary retention? J Urol 2002, 167:1705–1709.\nHubly JW, Thompson GJ: Infarction of the prostate and volumetric changes produced by the lesion. J Urol 1940, 43:459.\nSpiro LH, Labay G, Orkin LA: Prostatic infarction: role in acute urinary retention. Urology 1974, 3:345–347.\nAnjum I, Ahmed M, Azzopardi A, Mufti GR: Prostatic infarction\u002Finfection in acute urinary retention secondary to benign prostatic hyperplasia. J Urol 1998, 160:792–793.\nHargreave TB, Stephenson TP: Potency and prostatectomy. BrJ Urol 1977, 19:683–688. Perhaps one of the earliest studies addressing sexual function and prostatectomy.\nShimomura T, Kiyota H, Takahashi H, et al.: [Prostate histopathology of NIH category IV prostatitis detected by sextant prostate needle biopsy from the patients with high prostatic specific antigen]. Kansenshogaku Zasshi 2003, 77:611–617.\nCanfield PJ: A survey of koala road kills in New South Wales. J WildlDis 1991, 27:657–660.\nMoron G, Maletto B, Ropolo A, Pistoresi-Palencia MC: Changes in the development of experimental autoimmune prostatitis (EAP) by castration in aged rats. Dev Comp Immunol 2000, 24:673–682.\nNaslund MJ, Strandberg JD, Coffey DS: The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol 1988, 140:1049–1053.\nGarraway WM, Collins GN, Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet 1991, 338:469–471.\nJacobsen SJ, Jacobson DJ, Girman CJ, et al.: Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997, 158:481–487.\nMeigs JB, Barry MJ, Giovannucci E, et al.: Incidence rates and risk factors for acute urinary retention: the health professionals follow-up study. J Urol 1999, 162:376–382.\nMurray K, Massey A, Feneley RC: Acute urinary retention: a urodynamic assessment. Br J Urol 1984, 6:468–473.\nMcNeill AS, Rizvi S, Byrne DJ: Prostate size influences the outcome after presenting with acute urinary retention. BJU Int 2004, 94:559–562.\nKolman C, Girman CJ, Jacobsen SJ, et al.: Distribution of postvoid residual urine volume in randomly selected men. J Urol 1999, 161:122–127.\nMarberger MJ, Andersen JT, Nickel JC, et al.: Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention: combined experience from three large, multinational, placebo-controlled trials. Eur Urol 2000, 38:563–568.\nRoehrborn CG, Bruskewitz R, Nickel GC, et al.: Urinary retention in patients with BPH treated with finasteride or placebo over 4 years: characterization of patients and ultimate outcomes. PLESS Study Group. Eur Urol 2000, 37:528–536.\nDubey D, Kumar A, Kapoor R, et al.: Acute urinary retention: defining the need and timing for pressure-flow studies. BJU Int 2001, 88:178–182.\nMiyashita H, Kojima M, Miki T: Ultrasonic measurement of bladder weight as a possible predictor of acute urinary retention in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Ultrasound Med Biol 2002, 28:985–990.\nMcConnell JD, Roehrborn CG, Bautista OM, et al.: The longterm effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387–2398.\nMcNeill SA, Hargreave TB, Geffriaud-Ricouard C, et al.: Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. Urology 2001, 57:459–465.\nMcConnell JD, Bruskewitz R, Walsh P, et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998, 338:557–563.\nRoehrborn CG, Bruskewitz R, Nickel JC, et al.: Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 2004, 171:1194–1198.\nRoehrborn CG, Boyle P, Nickel JC, et al.: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60:434–441.\nAndriole GL, Humphrey P, Ray P, et al.: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004, 172:915–919. This is likely to be an important study because it benefits from some of the conundrums caused by the Prostate Cancer Prevention Trial finasteride data. If it can be clearly established that long-term 5α-reductase treatment is safe and even beneficial in terms of cancer risk, then medical treatment for lower urinary tract symptoms will become the treatment of choice for most men.\nDebruyne FM, Van der Poel HG: Clinical experience in Europe with uroselective al-antagonists. Eur Urol 1999, 36(suppl l):54–58.\nRoehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology 2001, 58(suppl 6A):55–63.\nChan PS, Wong WS, Chan LW, et al.: Can terazosin (alpha-blocker) relieve acute urinary retention and obviate the need for indwelling urethral catheter [Abstract 26]? BrJ Urol 1996, 77(suppl 1):7.\nMcNeill SA, Daruwala PD, Mitchell ID, et al.: Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled trial. BJU Int 1999, 84:622–627.\nBowden E, Hall S, Foley SJ, et al.: Tamsulosin in the treatment of urinary retention: a prospective, placebo-controlled trial [Abstract P148]. BJU Int 2001, 88:77.\nAbeygunasekera AM, de Silva S, Gurusingha A, Wijeratne S: Management of men with a first episode of acute urinary retention due to benign prostatic enlargement. Ceylon Med J 2001,46:124–125.\nKim HL, Kim JC, Benson DA, et al.: Results of treatment with tamsulosin in men with acute urinary retention. Tech Urol 2001, 7:256–260.\nLucas M, Stephenson T, Vinod N: Tamsulosin in the management of patients in acute urinary retention due to benign prostatic hyperplasia. Eur Urol 2002, 1:106.\nShah T, Palit V, Biyani S, et al.: Randomised, placebo-controlled, double-blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. Eur Urol 2002, 42:329–332.\nKaplan SA: A prospective study of conservatively managed acute urinary retention: prostate size matters. J Urol 2002, 168:402.\nHua LX, Wu HF, Sui YG, et al.: [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. Zhonghua Nan Ke Xue 2003, 9:510–511.\nLorente Garin JA, Canis Sanchez D, Arango Toro O, et al.: [Doxazosin in the gastrointestinal therapeutic system (GITS) formulation and trial without catheter after acute urinary retention due to BPH. Dose increase action on recovery effect]. Actas Urol Esp 2004, 28:32–37.\nRoehrborn C, Hargreave TB, McNeill SA, et al.: Influence of age on outcome of trial without catheter (TWOC) during alfuzosin 10 mg OD therapy in patients with acute urinary retention (AUR) related to BPH [Abstract 1366]. ALFAUR Study Group. J Urol 2004, 171(suppl):360.\nTan YH, Foo KT: Intravesical prostatic protrusion predicts the outcome of a trial without catheter following acute urine retention. J Urol 2003, 170:2339–2341.\nKlarskov P, Andersen JT, Asmussen CF, et al.: Symptoms and signs predictive of the voiding pattern after acute urinary retention in men. Scand J Urol Nephrol 1987, 21:23–28.\nMcNeill SA: Does acute urinary retention respond to alpha-blockers alone? Eur Urol 2001, 39(suppl 6):7–12.\nMcNeill SA, Hargreave TB, Roehrborn CG, Alfaur study group: Alfuzosin 10 mg once a day in the management of acute urinary retention: results of a double blind, placebo-controlled study. Urology 2005, 65:83–90.\nThompson IM, Goodman PJ, Tangen CM: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215–224.\nAndriole G, Bostwick D, Brawley O, et al.: Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004, 172:1314–1317.\nCaine M, Pfau A, Perlberg S: The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976, 48:255–263.\nBreum L, Klarskov P, Munck LK, et al.: Significance of acute urinary retention due to intravesical obstruction. Scand J Urol Nephrol 1982, 16:21–24.\nCraigen AA, Hickling JB, Saunders CR, et al.: Natural history of prostatic obstruction: a prospective survey. J R Coll Gen Pract 1969, 18:226–232.",{"EN":841},"This paper is restricted to the discussion of the relatively modern disorder of sudden painful inability to urinate in older men. It was not a common medical problem until the 19th century when, in developed countries, male life expectancy increased to beyond 60 years; it remains an uncommon problem in those developing countries where male life expectancy remains low, particularly in some sub-Saharan African countries where male life expectancy is only 44.8 years.",{"EN":843},"Acute urinary retention in men: The risks and outcomes with medical therapy",{"VOID":845},"10.1007\u002Fs11918-005-0004-6","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11918-005-0004-6",[848,855],{"id":849,"sortIndex":56,"researcher":20,"roles":850,"affiliations":851,"properties":852},"683d2165-c70e-426b-bc10-fe2b6e2af035",[87],[],{"title":853},{"VI":854},"Alan S. McNeill",{"id":856,"sortIndex":21,"researcher":20,"roles":857,"affiliations":858,"properties":867},"208a7a11-6d8f-4ca1-8154-084ca3186e4c",[87],[859],{"id":20,"sortIndex":21,"affiliation":860,"properties":20},{"id":861,"createTime":862,"updateTime":862,"relativeEntities":863,"slug":20,"properties":864,"entityType":107,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"96a3fa51-49bc-426e-969a-1406d28fc7c6","2023-12-28T13:49:14.773+00:00",[],{"title":865},{"VI":866},"Department of Oncology, Edinburgh University, Human Genetics Building, Western General Hospital, Edinburgh, UK",{"title":868},{"VI":869},"Timothy B. Hargreave",{"url":846,"publisher":871,"properties":891},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":872,"slug":10,"properties":873,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":877,"manageAffiliations":878,"indexDatabases":879,"url":20,"thumbnailPath":20,"statistic":886,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":874,"eissn":875,"title":876},{"VOID":13},{"VOID":15},{"EN":17},[],[],[880],{"id":26,"indexDatabase":881,"url":39,"indexYears":40,"academicFieldIds":20,"indexDatabaseRanking":41},{"id":28,"createTime":29,"updateTime":30,"relativeEntities":882,"label":883,"description":884,"key":36,"publicationTags":885,"standard":20},[],{"EN":33,"VI":33},{"EN":33,"VI":35},[38],{"impactFactor":21,"impactFactorByYear":887,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":44,"totalPublicationByYear":888,"totalCitation":52,"totalCitationByYear":889,"totalCitationPerPublication":57,"totalCitationPerPublicationByYear":890,"hindexLast5Year":55,"hindex":55},{},{"2003":46,"2004":47,"2005":48,"2006":48,"2007":49,"2008":50,"2009":51},{"2004":54,"2006":55,"2008":56},{"2004":59,"2006":60,"2008":57},{"volume":892,"pages":894},{"VOID":893},"3",{"VOID":895},"121-128","2005-09-01",2005]